1
|
Akinpelu A, Akinsipe T, Avila LA, Arnold RD, Mistriotis P. The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression. Cancer Metastasis Rev 2024:10.1007/s10555-024-10166-x. [PMID: 38238542 DOI: 10.1007/s10555-024-10166-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 01/02/2024] [Indexed: 01/30/2024]
Abstract
Metastasis accounts for the vast majority of breast cancer-related fatalities. Although the contribution of genetic and epigenetic modifications to breast cancer progression has been widely acknowledged, emerging evidence underscores the pivotal role of physical stimuli in driving breast cancer metastasis. In this review, we summarize the changes in the mechanics of the breast cancer microenvironment and describe the various forces that impact migrating and circulating tumor cells throughout the metastatic process. We also discuss the mechanosensing and mechanotransducing molecules responsible for promoting the malignant phenotype in breast cancer cells. Gaining a comprehensive understanding of the mechanobiology of breast cancer carries substantial potential to propel progress in prognosis, diagnosis, and patient treatment.
Collapse
Affiliation(s)
- Ayuba Akinpelu
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL, 36849, USA
| | - Tosin Akinsipe
- Department of Biological Sciences, College of Science and Mathematics, Auburn University, Auburn, AL, 36849, USA
| | - L Adriana Avila
- Department of Biological Sciences, College of Science and Mathematics, Auburn University, Auburn, AL, 36849, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, 36849, USA
| | - Panagiotis Mistriotis
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL, 36849, USA.
| |
Collapse
|
2
|
Habbit NL, Anbiah B, Suresh J, Anderson L, Davies ML, Hassani I, Ghosh TM, Greene MW, Prabhakarpandian B, Arnold RD, Lipke EA. Ratiometric Inclusion of Fibroblasts Promotes Both Castration-Resistant and Androgen-Dependent Tumorigenic Progression in Engineered Prostate Cancer Tissues. Adv Healthc Mater 2023; 12:e2301139. [PMID: 37450342 DOI: 10.1002/adhm.202301139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 06/30/2023] [Accepted: 07/12/2023] [Indexed: 07/18/2023]
Abstract
To investigate the ratiometric role of fibroblasts in prostate cancer (PCa) progression, this work establishes a matrix-inclusive, 3D engineered prostate cancer tissue (EPCaT) model that enables direct coculture of neuroendocrine-variant castration-resistant (CPRC-ne) or androgen-dependent (ADPC) PCa cells with tumor-supporting stromal cell types. Results show that the inclusion of fibroblasts within CRPC-ne and ADPC EPCaTs drives PCa aggression through significant matrix remodeling and increased proliferative cell populations. Interestingly, this is observed to a much greater degree in EPCaTs formed with a small number of fibroblasts relative to the number of PCa cells. Fibroblast coculture also results in ADPC behavior more similar to the aggressive CRPC-ne condition, suggesting fibroblasts play a role in elevating PCa disease state and may contribute to the ADPC to CRPC-ne switch. Bulk transcriptomic analyses additionally elucidate fibroblast-driven enrichment of hallmark gene sets associated with tumorigenic progression. Finally, the EPCaT model clinical relevancy is probed through a comparison to the Cancer Genome Atlas (TCGA) PCa patient cohort; notably, similar gene set enrichment is observed between EPCaT models and the patient primary tumor transcriptome. Taken together, study results demonstrate the potential of the EPCaT model to serve as a PCa-mimetic tool in future therapeutic development efforts.
Collapse
Affiliation(s)
- Nicole L Habbit
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| | - Benjamin Anbiah
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| | - Joshita Suresh
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| | - Luke Anderson
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| | - Megan L Davies
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| | - Iman Hassani
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| | - Taraswi M Ghosh
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 720 So. Donahue Dr., Pharmaceutical Research Building, Auburn, AL, 36849, USA
| | - Michael W Greene
- Department of Nutritional Sciences, College of Human Sciences, Auburn University, 210 Spidle Hall, Auburn, AL, 36849, USA
| | | | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 720 So. Donahue Dr., Pharmaceutical Research Building, Auburn, AL, 36849, USA
| | - Elizabeth A Lipke
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL, 36849, USA
| |
Collapse
|
3
|
Covington EW, Jasper-Trotter SL, Arnold RD, Amin R, Egbert S, Chung A. Prospective pilot study evaluating a vitamin D3 loading dose in critically ill children with vitamin D deficiency. Fundam Clin Pharmacol 2023. [PMID: 38010094 DOI: 10.1111/fcp.12973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 10/20/2023] [Accepted: 11/08/2023] [Indexed: 11/29/2023]
Abstract
BACKGROUND Vitamin D deficiency is a common finding in critically ill children. However, the optimal supplementation strategy in this patient population is unknown. The objective of this study was to evaluate the effects of high-dose (10 000 IU/kg, max. 400 000 IU) vitamin D supplementation on 25-hydroxyvitamin D3 (25[OH]D3) levels in pediatric intensive care unit (PICU) patients with baseline vitamin D deficiency. METHODS This was a prospective, institutional review board-approved pilot research study performed at the University of South Alabama Women's and Children's Hospital in Mobile, AL. The study sample consisted of patients less than 18 years old admitted to the PICU with baseline 25-hydroxyvitamin D (25[OH]D) level less than 30 ng/ml. Included patients received a one-time dose of vitamin D3 orally or via gastric tube (10 000 IU/kg, max. 400 000 IU). RESULTS A total of 17 patients were screened with 11 included in the study. Blood analysis revealed a significant increase in 25(OH)D3 level from baseline to 12-h post dose (21.6 [4.5] ng/ml vs. 46.7 [15.5] ng/ml, P < 0.001). At the 12-h post-dose time point, 10/11 patients (91%) had 25(OH)D3 levels that were greater than 30 ng/ml. No adverse effects were observed. CONCLUSION Vitamin D3 supplementation at a dose of 10 000 IU/kg (max. 400 000 IU) significantly increased 25(OH)D3 levels in critically ill pediatric patients.
Collapse
Affiliation(s)
| | | | - Robert D Arnold
- Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA
| | - Raj Amin
- Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA
| | - Susan Egbert
- University of Manitoba, Winnipeg, Manitoba, Canada
| | - Allison Chung
- Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA
| |
Collapse
|
4
|
Alhowail AH, Eggert M, Bloemer J, Pinky PD, Woodie L, Bhattacharya S, Bhattacharya D, Buabeid MA, Smith B, Dhanasekaran M, Piazza G, Reed MN, Escobar M, Arnold RD, Suppiramaniam V. Phenyl-2-aminoethyl selenide ameliorates hippocampal long-term potentiation and cognitive deficits following doxorubicin treatment. PLoS One 2023; 18:e0294280. [PMID: 37948406 PMCID: PMC10637675 DOI: 10.1371/journal.pone.0294280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 10/30/2023] [Indexed: 11/12/2023] Open
Abstract
Chemotherapy-induced memory loss ("chemobrain") can occur following treatment with the widely used chemotherapeutic agent doxorubicin (DOX). However, the mechanisms through which DOX induces cognitive dysfunction are not clear, and there are no commercially available therapies for its treatment or prevention. Therefore, the aim of this study was to determine the therapeutic potential of phenyl-2-aminoethyl selenide (PAESe), an antioxidant drug previously demonstrated to reduce cardiotoxicity associated with DOX treatment, against DOX-induced chemobrain. Four groups of male athymic NCr nude (nu/nu) mice received five weekly tail-vein injections of saline (Control group), 5 mg/kg of DOX (DOX group), 10 mg/kg PAESe (PAESe group), or 5 mg/kg DOX and 10 mg/kg PAESe (DOX+PAESe group). Spatial memory was evaluated using Y-maze and novel object location tasks, while synaptic plasticity was assessed through the measurement of field excitatory postsynaptic potentials from the Schaffer collateral circuit. Western blot analyses were performed to assess hippocampal protein and phosphorylation levels. In this model, DOX impaired synaptic plasticity and memory, and increased phosphorylation of protein kinase B (Akt) and extracellular-regulated kinase (ERK). Co-administration of PAESe reduced Akt and ERK phosphorylation and ameliorated the synaptic and memory deficits associated with DOX treatment.
Collapse
Affiliation(s)
- Ahmad H. Alhowail
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
- Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Kingdom of Saudi Arabia
| | - Matthew Eggert
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
| | - Jenna Bloemer
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
| | - Priyanka D. Pinky
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
| | - Lauren Woodie
- Department of Nutrition, Dietetics and Hospitality Management, College of Human Sciences, Auburn University, Auburn, AL, United States of America
| | - Subhrajit Bhattacharya
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
| | - Dwipayan Bhattacharya
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
| | - Manal A. Buabeid
- College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE
| | - Bruce Smith
- Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States of America
| | - Muralikrishnan Dhanasekaran
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, United States of America
| | - Gary Piazza
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
| | - Miranda N. Reed
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, United States of America
| | - Martha Escobar
- Department of Psychology, Oakland University, Rochester, MI, United States of America
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, United States of America
| | - Vishnu Suppiramaniam
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States of America
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, United States of America
- Department of Molecular and Cellular Biology, College of Science and Mathematics, Kennesaw State University, Kennesaw, Georgia
| |
Collapse
|
5
|
Kennerly R, Coleman AE, Jasper SL, Arnold RD, Brainard BM. Effects of orally administered pimobendan on platelet function in healthy adult cats. Am J Vet Res 2023; 84:ajvr.23.05.0103. [PMID: 37491004 DOI: 10.2460/ajvr.23.05.0103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 07/03/2023] [Indexed: 07/27/2023]
Abstract
OBJECTIVE Several phosphodiesterase inhibitors have demonstrable antiplatelet actions when administered to human patients. Concentration-dependent inhibition of feline platelet aggregation by pimobendan has been previously demonstrated in vitro. However, there are no published reports characterizing the effect of oral pimobendan, administered at therapeutic doses, on platelet function in cats. This study aimed to evaluate the effect of orally administered pimobendan on platelet function in healthy adult cats. ANIMALS 6 healthy purpose-bred adult cats. METHODS Cats were administered pimobendan orally at a dosage of 0.625 mg/cat (low-dose) twice daily for 1 week, followed by 1.25 mg/cat (high-dose) twice daily for 1 week. Venous blood sampling for platelet testing and plasma drug concentration occurred at baseline, 1 hour postdose on the eighth day of treatment with low-dose pimobendan, 1 hour postdose on the eighth day of treatment with high-dose pimobendan, and after a 1-week washout period. Platelet function was assessed by whole blood aggregometry and by use of a platelet function analyzer (PFA-100®). Friedman tests were used to compare platelet function parameters among the 4 sampling timepoints. RESULTS After 1 week of treatment, median (range) plasma pimobendan concentrations were 15.1 ng/mL (6.89-20.2 ng/mL) and 32.8 ng/mL (23.3-44.8 ng/mL) in cats receiving low-dose and high-dose pimobendan, respectively. No significant differences in PFA closure time or any aggregometry variable were found among the treatment conditions. CLINICAL RELEVANCE Pimobendan was not associated with measurable inhibition of platelet function when administered orally to healthy adult cats at 2 clinically relevant dosages.
Collapse
Affiliation(s)
- Rebecca Kennerly
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA
| | - Amanda E Coleman
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA
| | - Shanese L Jasper
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL
| | - Robert D Arnold
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL
| | - Benjamin M Brainard
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA
| |
Collapse
|
6
|
Poudel I, Annaji M, Zhang C, Panizzi PR, Arnold RD, Kaddoumi A, Amin RH, Lee S, Shamsaei N, Babu RJ. Gentamicin Eluting 3D-Printed Implants for Preventing Post-Surgical Infections in Bone Fractures. Mol Pharm 2023; 20:4236-4255. [PMID: 37455392 DOI: 10.1021/acs.molpharmaceut.3c00373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]
Abstract
A surgically implantable device is an inevitable treatment option for millions of people worldwide suffering from diseases arising from orthopedic injuries. A global paradigm shift is currently underway to tailor and personalize replacement or reconstructive joints. Additive manufacturing (AM) has provided dynamic outflow to the customized fabrication of orthopedic implants by enabling need-based design and surface modification possibilities. Surgical grade 316L Stainless Steel (316L SS) is promising with its cost, strength, composition, and corrosion resistance to fabricate 3D implants. This work investigates the possibilities of application of the laser powder bed fusion (L-PBF) technique to fabricate 3D-printed (3DP) implants, which are functionalized with a multilayered antimicrobial coating to treat potential complications arising due to postsurgical infections (PSIs). Postsurgical implant-associated infection is a primary reason for implantation failure and is complicated mainly by bacterial colonization and biofilm formation at the installation site. PLGA (poly-d,l-lactide-co-glycolide), a biodegradable polymer, was utilized to impart multiple layers of coating using the airbrush spray technique on 3DP implant surfaces loaded with gentamicin (GEN). Various PLGA-based polymers were tested to optimize the ideal lactic acid: glycolic acid ratio and molecular weight suited for our investigation. 3D-Printed PLGA-GEN substrates sustained the release of gentamicin from the surface for approximately 6 weeks. The 3DP surface modification with PLGA-GEN facilitated cell adhesion and proliferation compared to control surfaces. The cell viability studies showed that the implants were safe for application. The 3DP PLGA-GEN substrates showed good concentration-dependent antibacterial efficacy against the common PSI pathogen Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis). The GEN-loaded substrates demonstrated antimicrobial longevity and showed significant biofilm growth inhibition compared to control. The substrates offered great versatility regarding the in vitro release rates, antimicrobial properties, and biocompatibility studies. These results radiate great potential in future human and veterinary clinical applications pertinent to complications arising from PSIs, focusing on personalized sustained antibiotic delivery.
Collapse
Affiliation(s)
- Ishwor Poudel
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Manjusha Annaji
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Chu Zhang
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Peter R Panizzi
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Amal Kaddoumi
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Rajesh H Amin
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| | - Seungjong Lee
- Department of Mechanical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, Alabama 36849, United States
- National Center for Additive Manufacturing Excellence (NCAME), Auburn University, Auburn, Alabama 36849, United States
| | - Nima Shamsaei
- Department of Mechanical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, Alabama 36849, United States
- National Center for Additive Manufacturing Excellence (NCAME), Auburn University, Auburn, Alabama 36849, United States
| | - R Jayachandra Babu
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama 36849, United States
| |
Collapse
|
7
|
Mitra Ghosh T, Mazumder S, Davis J, Yadav J, Akinpelu A, Alnaim A, Kumar H, Waliagha R, Church Bird AE, Rais-Bahrami S, Bird RC, Mistriotis P, Mishra A, Yates CC, Mitra AK, Arnold RD. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Res Commun 2023; 3:1286-1311. [PMID: 37476073 PMCID: PMC10355222 DOI: 10.1158/2767-9764.crc-22-0427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 03/29/2023] [Accepted: 06/21/2023] [Indexed: 07/22/2023]
Abstract
Prostate cancer is the second leading cause of noncutaneous cancer-related deaths in American men. Androgen deprivation therapy (ADT), radical prostatectomy, and radiotherapy remain the primary treatment for patients with early-stage prostate cancer (castration-sensitive prostate cancer). Following ADT, many patients ultimately develop metastatic castration-resistant prostate cancer (mCRPC). Standard chemotherapy options for CRPC are docetaxel (DTX) and cabazitaxel, which increase median survival, although the development of resistance is common. Cancer stem-like cells possess mesenchymal phenotypes [epithelial-to-mesenchymal transition (EMT)] and play crucial roles in tumor initiation and progression of mCRPC. We have shown that low-dose continuous administration of topotecan (METRO-TOPO) inhibits prostate cancer growth by interfering with key cancer pathway genes. This study utilized bulk and single-cell or whole-transcriptome analysis [(RNA sequencing (RNA-seq) and single-cell RNA sequencing (scRNA-seq)], and we observed greater expression of several EMT markers, including Vimentin, hyaluronan synthase-3, S100 calcium binding protein A6, TGFB1, CD44, CD55, and CD109 in European American and African American aggressive variant prostate cancer (AVPC) subtypes-mCRPC, neuroendocrine variant (NEPC), and taxane-resistant. The taxane-resistant gene FSCN1 was also expressed highly in single-cell subclonal populations in mCRPC. Furthermore, metronomic-topotecan single agent and combinations with DTX downregulated these EMT markers as well as CD44+ and CD44+/CD133+ "stem-like" cell populations. A microfluidic chip-based cell invasion assay revealed that METRO-TOPO treatment as a single agent or in combination with DTX was potentially effective against invasive prostate cancer spread. Our RNA-seq and scRNA-seq analysis were supported by in silico and in vitro studies, suggesting METRO-TOPO combined with DTX may inhibit oncogenic progression by reducing cancer stemness in AVPC through the inhibition of EMT markers and multiple oncogenic factors/pathways. Significance The utilization of metronomic-like dosing regimens of topotecan alone and in combination with DTX resulted in the suppression of makers associated with EMT and stem-like cell populations in AVPC models. The identification of molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression were achieved using bulk RNA-seq and single-cell-omics methodologies.
Collapse
Affiliation(s)
- Taraswi Mitra Ghosh
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
- Division of Urology, Department of Surgery, Mass General Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Suman Mazumder
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
- Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Harrison College of Pharmacy, Auburn University, Auburn, Alabama
| | - Joshua Davis
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
| | - Jyoti Yadav
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama
| | - Ayuba Akinpelu
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, Alabama
| | - Ahmed Alnaim
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
| | - Harish Kumar
- Department of Biology and Canter for Cancer Research, Tuskegee University, Tuskegee, Alabama
| | - Razan Waliagha
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
| | - Allison E. Church Bird
- Flow Cytometry and High-Speed Cell Sorting Laboratory, Auburn University, Auburn, Alabama
| | - Soroush Rais-Bahrami
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
- Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
- Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
- Department of Pathology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
| | - R. Curtis Bird
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama
| | - Panagiotis Mistriotis
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, Alabama
| | - Amarjit Mishra
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama
| | - Clayton C. Yates
- Department of Biology and Canter for Cancer Research, Tuskegee University, Tuskegee, Alabama
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
- Department of Pathology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Amit K. Mitra
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
- Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Harrison College of Pharmacy, Auburn University, Auburn, Alabama
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, Alabama
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
| |
Collapse
|
8
|
Vigneault A, Mylniczenko ND, Arnold RD, Jasper-Trotter SL, Summa N, Rousseau C, Vergneau-Grosset C. MANAGEMENT OF SUSPECTED DILATED CARDIOMYOPATHY WITH PIMOBENDAN IN TWO LEOPARD SHARKS ( TRIAKIS SEMIFASCIATA). J Zoo Wildl Med 2023; 54:401-405. [PMID: 37428706 DOI: 10.1638/2022-0084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/23/2022] [Indexed: 07/12/2023] Open
Abstract
Two adult male leopard sharks (Triakis semifasciata) under managed care were diagnosed with suspected dilated cardiomyopathy. Clinical signs included lethargy, inappetence, and regurgitation. On cardiac ultrasound, fractional shortening was 14% and 10%, respectively (versus 21%-31% in four healthy conspecifics). Ventricular end-diastolic diameter to body weight ratio was 1.72 cm/kg in Case 1 (versus 0.52-1.24 cm/kg in four conspecifics). These results collectively suggested a dilated cardiomyopathy. Treatment was implemented with oral pimobendan at 0.3 mg/kg q48h for 1 mon. The pimobendan dose was increased to 0.5 mg/kg 3/wk, following plasmatic dosage of pimobendan and its metabolite. After 3 mon, fractional shortening increased to 38% and 20%, respectively, sharks regained a normal appetite, and body weight increased by 50% in one individual. After 2 yr, both individuals remained clinically normal, and no adverse effect was noted with pimobendan administration. Pimobendan plasma concentration suggested that this medication was well absorbed in this species.
Collapse
Affiliation(s)
- Annabelle Vigneault
- Centre hospitalier universitaire vétérinaire affiliated with the Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada
| | - Natalie D Mylniczenko
- Disney's Animals, Science and Environment, Walt Disney World, Lake Buena Vista, FL 32830, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Shanese L Jasper-Trotter
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Noémie Summa
- Centre hospitalier universitaire vétérinaire affiliated with the Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada
| | | | - Claire Vergneau-Grosset
- Département de sciences cliniques, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada,
| |
Collapse
|
9
|
Davis JT, Ghosh TM, Mazumder S, Mitra A, Bird RC, Arnold RD. Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial-Mesenchymal Transition. Int J Mol Sci 2023; 24:ijms24108490. [PMID: 37239838 DOI: 10.3390/ijms24108490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 05/02/2023] [Accepted: 05/04/2023] [Indexed: 05/28/2023] Open
Abstract
Maximum tolerable dosing (MTD) of chemotherapeutics has long been the gold standard for aggressive malignancies. Recently, alternative dosing strategies have gained traction for their improved toxicity profiles and unique mechanisms of action, such as inhibition of angiogenesis and stimulation of immunity. In this article, we investigated whether extended exposure (EE) topotecan could improve long-term drug sensitivity by preventing drug resistance. To achieve significantly longer exposure times, we used a spheroidal model system of castration-resistant prostate cancer. We also used state-of-the-art transcriptomic analysis to further elucidate any underlying phenotypic changes that occurred in the malignant population following each treatment. We determined that EE topotecan had a much higher barrier to resistance relative to MTD topotecan and was able to maintain consistent efficacy throughout the study period (EE IC50 of 54.4 nM (Week 6) vs. MTD IC50 of 2200 nM (Week 6) vs. 83.8 nM IC50 for control (Week 6) vs. 37.8 nM IC50 for control (Week 0)). As a possible explanation for these results, we determined that MTD topotecan stimulated epithelial-mesenchymal transition (EMT), upregulated efflux pumps, and produced altered topoisomerases relative to EE topotecan. Overall, EE topotecan resulted in a more sustained treatment response and maintained a less aggressive malignant phenotype relative to MTD topotecan.
Collapse
Affiliation(s)
- Joshua T Davis
- Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849, USA
| | - Taraswi Mitra Ghosh
- Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849, USA
- Department of Urology Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA
| | - Suman Mazumder
- Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849, USA
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35233, USA
| | - Amit Mitra
- Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849, USA
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35233, USA
- Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Richard Curtis Bird
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849, USA
- UAB O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35233, USA
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| |
Collapse
|
10
|
Poudel I, Annaji M, Wibowo FS, Arnold RD, Fasina O, Via B, Rangari V, Peresin MS, Smith F, Dhanasekaran M, Tiwari AK, Babu RJ. Hispolon Cyclodextrin Complexes and Their Inclusion in Liposomes for Enhanced Delivery in Melanoma Cell Lines. Int J Mol Sci 2022; 23:ijms232214487. [PMID: 36430965 PMCID: PMC9695989 DOI: 10.3390/ijms232214487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 11/11/2022] [Accepted: 11/17/2022] [Indexed: 11/23/2022] Open
Abstract
Hispolon, a phenolic pigment isolated from the mushroom species Phellinus linteus, has been investigated for anti-inflammatory, antioxidant, and anticancer properties; however, low solubility and poor bioavailability have limited its potential clinical translation. In this study, the inclusion complex of hispolon with Sulfobutylether-β-cyclodextrin (SBEβCD) was characterized, and the Hispolon-SBEβCD Complex (HSC) was included within the sterically stabilized liposomes (SL) to further investigate its anticancer activity against melanoma cell lines. The HSC-trapped-Liposome (HSC-SL) formulation was investigated for its sustained drug delivery and enhanced cytotoxicity. The inclusion complex in the solid=state was confirmed by a Job’s plot analysis, molecular modeling, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), Proton nuclear magnetic resonance (NMR) spectroscopy, and scanning electron microscopy (SEM). The HSC-SL showed no appreciable deviation in size (<150 nm) and polydispersity index (<0.2) and improved drug encapsulation efficiency (>90%) as compared to control hispolon liposomes. Individually incorporated hispolon and SBEβCD in the liposomes (H-CD-SL) was not significant in loading the drug in the liposomes, compared to HSC-SL, as a substantial amount of free drug was separated during dialysis. The HSC-SL formulation showed a sustained release compared to hispolon liposomes (H-SLs) and Hispolon-SBEβCD liposomes (H-CD-SLs). The anticancer activity on melanoma cell lines (B16BL6) of HSC and HSC-SL was higher than in H-CD-SL and hispolon solution. These findings suggest that HSC inclusion in the HSC-SL liposomes stands out as a potential formulation approach for enhancing drug loading, encapsulation, and chemotherapeutic efficiency of hispolon and similar water insoluble drug molecules.
Collapse
Affiliation(s)
- Ishwor Poudel
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Manjusha Annaji
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Fajar Setyo Wibowo
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Oladiran Fasina
- Department of Biosystems Engineering, Auburn University, Auburn, AL 36849, USA
| | - Brian Via
- Forest Products Development Center, Auburn University, Auburn, AL 36849, USA
| | - Vijaya Rangari
- Department of Material Science Engineering, Tuskegee University, Tuskegee, AL 36088, USA
| | - Maria Soledad Peresin
- Sustainable Bio-Based Materials Laboratory, Forest Products Development Center, College of Forestry, Wildlife and Environment, Auburn University, 602 Duncan Drive, Auburn, AL 36849, USA
| | - Forrest Smith
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Muralikrishnan Dhanasekaran
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Amit K. Tiwari
- Department of Pharmacology & Experimental Therapeutics, Health Science Campus, The University of Toledo, 3000 Arlington Ave., Toledo, OH 43614, USA
- Correspondence: (A.K.T.); (R.J.B.)
| | - R. Jayachandra Babu
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA
- Correspondence: (A.K.T.); (R.J.B.)
| |
Collapse
|
11
|
Feugang JM, Ishak GM, Eggert MW, Arnold RD, Rivers OS, Willard ST, Ryan PL, Gastal EL. Intrafollicular injection of nanomolecules for advancing knowledge on folliculogenesis in livestock. Theriogenology 2022; 192:132-140. [DOI: 10.1016/j.theriogenology.2022.08.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 08/15/2022] [Accepted: 08/22/2022] [Indexed: 11/25/2022]
|
12
|
Habbit NL, Anbiah B, Anderson L, Suresh J, Hassani I, Eggert M, Brannen A, Davis J, Tian Y, Prabhakarpandian B, Panizzi P, Arnold RD, Lipke EA. Tunable three-dimensional engineered prostate cancer tissues for in vitro recapitulation of heterogeneous in vivo prostate tumor stiffness. Acta Biomater 2022; 147:73-90. [PMID: 35551999 DOI: 10.1016/j.actbio.2022.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 04/21/2022] [Accepted: 05/05/2022] [Indexed: 11/24/2022]
Abstract
In this manuscript we report the establishment and characterization of a three-dimensional in vitro, coculture engineered prostate cancer tissue (EPCaT) disease model based upon and informed by our characterization of in vivo prostate cancer (PCa) xenograft tumor stiffness. In prostate cancer, tissue stiffness is known to impact changes in gene and protein expression, alter therapeutic response, and be positively correlated with an aggressive clinical presentation. To inform an appropriate stiffness range for our in vitro model, PC-3 prostate tumor xenografts were established. Tissue stiffness ranged from 95 to 6,750 Pa. Notably, xenograft cell seeding density significantly impacted tumor stiffness; a two-fold increase in the number of seeded cells not only widened the tissue stiffness range throughout the tumor but also resulted in significant spatial heterogeneity. To fabricate our in vitro EPCaT model, PC-3 castration-resistant prostate cancer cells were co-encapsulated with BJ-5ta fibroblasts within a poly(ethylene glycol)-fibrinogen matrix augmented with excess poly(ethylene glycol)-diacrylate to modulate the matrix mechanical properties. Encapsulated cells temporally remodeled their in vitro microenvironment and enrichment of gene sets associated with tumorigenic progression was observed in response to increased matrix stiffness. Through variation of matrix composition and culture duration, EPCaTs were tuned to mimic the wide range of biomechanical cues provided to PCa cells in vivo; collectively, a range of 50 to 10,000 Pa was achievable. Markedly, this also encompasses published clinical PCa stiffness data. Overall, this study serves to introduce our bioinspired, tunable EPCaT model and provide the foundation for future PCa progression and drug development studies. STATEMENT OF SIGNIFICANCE: The development of cancer models that mimic the native tumor microenvironment (TME) complexities is critical to not only develop effective drugs but also enhance our understanding of disease progression. Here we establish and characterize our 3D in vitro engineered prostate cancer tissue model with tunable matrix stiffness, that is inspired by this study's spatial characterization of in vivo prostate tumor xenograft stiffness. Notably, our model's mimicry of the TME is further augmented by the inclusion of matrix remodeling fibroblasts to introduce cancer-stromal cell-cell interactions. This study addresses a critical unmet need in the field by elucidating the prostate tumor xenograft stiffness range and establishing a foundation for recapitulating the biomechanics of site-of-origin and soft tissue metastatic prostate tumors in vitro.
Collapse
Affiliation(s)
- Nicole L Habbit
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA
| | - Benjamin Anbiah
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA
| | - Luke Anderson
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA
| | - Joshita Suresh
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA
| | - Iman Hassani
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA
| | - Matthew Eggert
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 362 Thach Concourse, Auburn, AL 36849, USA
| | - Andrew Brannen
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 362 Thach Concourse, Auburn, AL 36849, USA
| | - Joshua Davis
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 362 Thach Concourse, Auburn, AL 36849, USA
| | - Yuan Tian
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA
| | | | - Peter Panizzi
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 362 Thach Concourse, Auburn, AL 36849, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 362 Thach Concourse, Auburn, AL 36849, USA
| | - Elizabeth A Lipke
- Department of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, 212 Ross Hall, Auburn, AL 36849, USA.
| |
Collapse
|
13
|
Habbit NL, Anbiah B, Suresh J, Tian Y, Anderson LS, Davies ML, Hassani I, Ghosh TM, Prabhakarpandian B, Arnold RD, Lipke EA. Abstract 3856: Elucidating the role of fibroblasts in CRPC and ADPC progression using 3D engineered prostate cancer tissues. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate cancer (PC) currently represents 7.5% of all new cancer cases; notably, the 5-year relative survival rate drops from 100% in localized cases to 30.2% in patients who present with metastases. There are no curative therapies for metastatic PC, and most men develop serial resistance to androgen suppression, resulting in a more aggressive disease state that is much more difficult to mitigate.
Fibroblasts have been implicated in cancer progression and are thought to intravasate alongside circulating tumor cells and prime metastatic sites for tumor growth. Our understanding of the precise mechanisms by which they contribute to PC, however, is relatively underdeveloped in comparison to other solid cancer types. Here, we report a three-dimensional (3D) engineered prostate cancer tissue (EPCaT) model comprised of PC-3 castration-resistant (CRPC) or LNCaP androgen-dependent (ADPC) PC cell lines in direct coculture with BJ-5ta fibroblasts. By specifically isolating this cell-cell interaction within a bioinspired poly(ethylene glycol)-fibrinogen (PF) matrix, our EPCaT model introduces the ability to monitor coculture-driven changes at a tissue, cellular, and transcriptomic level.
Temporal variations in EPCaT growth, cell and colony morphology, cell populations, and cell-mediated remodeling of the PF matrix were assessed. Changes in bulk transcriptomic expression were also quantified and differentially expressed genes (DEGs) were evaluated between CRPC and ADPC mono- and coculture conditions. Finally, to evaluate the clinical significance of our findings, EPCaTs were evaluated against normal and primary tumor tissue transcriptomic data acquired from the Cancer Genome Atlas (TCGA).
In comparison to monoculture EPCaTs, both CRPC- and ADPC-fibroblast coculture conditions resulted in an increase in the number of proliferative cells, morphological features of cancer cell migration, and cell-mediated remodeling of the PF matrix, all of which suggest a more aggressive cell phenotype. DEG and gene ontology analysis revealed coculture-driven changes in genes associated with important tumorigenic processes including ECM organization, angiogenesis, and epithelial cell proliferation and migration. Interestingly, fibroblast coculture had a significantly larger impact on the ADPC transcriptome in comparison to CRPC, suggesting that fibroblasts could play an elevated role in less aggressive disease states. Notable DEGs in ADPC coculture that were also clinically significant in the TCGA tumor versus normal comparison included an overexpression of OR51E2 which has been shown to increase epithelial cell proliferation and participate in the ADPC to CRPC switch, thus exacerbating PC progression. Future studies will augment the pathophysiological relevance of our EPCaT model by including patient-isolated cancer-associated fibroblasts from recurring and non-recurring patients.
Citation Format: Nicole L. Habbit, Benjamin Anbiah, Joshita Suresh, Yuan Tian, Luke S. Anderson, Megan L. Davies, Iman Hassani, Taraswi Mitra Ghosh, Balabhaskar Prabhakarpandian, Robert D. Arnold, Elizabeth A. Lipke. Elucidating the role of fibroblasts in CRPC and ADPC progression using 3D engineered prostate cancer tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3856.
Collapse
|
14
|
Alrbyawi H, Poudel I, Annaji M, Arnold RD, Tiwari AK, Babu RJ. Recent Advancements of Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery. Pharm Nanotechnol 2022; 10:3-23. [PMID: 35156590 DOI: 10.2174/2211738510666220214102626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 01/09/2022] [Accepted: 01/18/2022] [Indexed: 11/22/2022]
Abstract
Liposomes have gained attention as a well-accepted nanocarrier for several chemotherapeutic drugs and are considered a drug delivery system of choice for a wide range of products. These amphipathic spherical vesicles primarily consist of one or more phospholipid bilayers, showing promise for drug delivery of both hydrophilic and hydrophobic components in addition to unique properties such as biocompatibility, biodegradability, low toxicity, and non-immunogenicity. Recent advances in liposomes are mainly centered on chemical and structural modification with the multifunctional approach to target the cancer cells activating the offensive mechanisms within the proximity of the tumors. Stimuli-responsive liposomes are a precisive approach to deliver and release chemotherapeutic drugs in the tumor site in a controlled fashion, thus reducing damage to normal tissues and preventing the side effects of the conventional chemotherapy regimen. The unique characteristics in the tumor microenvironment facilitate applying an endogenous stimulus (pH, redox potential, or enzymatic activity) to trigger the release of the drug, or external stimulus (heat or light) could be applied to tailor the drug release from liposomes. This review focuses on newer developments in stimuli-sensitive liposomal drug delivery systems designed to apply either exogenous (temperature, light, and magnetic field) or endogenous (pH changes, enzymatic triggers, or redox potential) approaches.
Collapse
Affiliation(s)
- Hamad Alrbyawi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849, USA
- Pharmaceutics and Pharmaceutical Technology Department, College of Pharmacy, Taibah University, Medina, Saudi Arabia
| | - Ishwor Poudel
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849, USA
| | - Manjusha Annaji
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849, USA
| | - Amit K Tiwari
- Department of Pharmacology and Experimental Therapeutics, The University of Toledo, Toledo, Ohio, 43614, USA
| | - R Jayachandra Babu
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849, USA
| |
Collapse
|
15
|
Mitra Ghosh T, Kansom T, Mazumder S, Davis J, Alnaim AS, Jasper SL, Zhang C, Bird A, Opanasopit P, Mitra AK, Arnold RD. The Andrographolide analogue 3A.1 synergizes with Taxane derivatives in aggressive metastatic prostate cancers by upregulation of Heat Shock proteins and downregulation of MAT2A-mediated cell migration and invasion. J Pharmacol Exp Ther 2021; 380:180-201. [PMID: 34949650 DOI: 10.1124/jpet.121.000898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Accepted: 12/06/2021] [Indexed: 11/22/2022] Open
Abstract
Conventional treatment with taxanes (docetaxel-DTX or cabazitaxel-CBZ) increases survival rates of aggressive metastatic castration resistant prostate cancer (mCRPC) to some extent since the majority of patients acquire resistance to taxanes. The andrographolide analogue, 19-tert-butyldiphenylsilyl-8,7-epoxy andrographolide (3A.1), has shown anticancer activity against various cancers. In this study, we investigated the effect of 3A.1 alone and in combination with DTX/CBZ against mCRPC and their mechanism of action. Exposure to 3A.1 alone exhibited a dose- and time-dependent antitumor activity in mCRPC. Chou-Talalay's combination index (CI) values of all 3A.1+ TX combinations were less than 0.5, indicating synergism. Co-treatment of 3A.1 with TX reduced the required dose of DTX and CBZ (p<0.05). Caspase assay (apoptosis) results concurred with in vitro cytotoxicity data. RNAseq followed by IPA analysis identified that upregulation of heat-shock proteins (Hsp70, Hsp40, Hsp27 and Hsp90) and downregulation of MAT2A as the key player for 3A.1 response. Further, the top treatment-induced DEGs belong to DNA damage, cell migration, hypoxia, autophagy (MMP1, MMP9, HIF-1α, Bag-3, H2AX, HMOX1, PSRC1) and cancer progression pathways. Most importantly, top downregulated DEG MAT2A has earlier been shown to be involved in cell migration and invasion. Further, using in silico analysis on the TCGA database, we found that MAT2A and highly co-expressed (r>0.7) genes, TRA2B and SF1, were associated with worse Gleason score and nodal metastasis status in prostate adenocarcinoma patients (PRAD-TCGA). Immunoblotting, COMET, and migration assays corroborated these findings. These results suggest that 3A.1 may be useful in increasing the anticancer efficacy of taxanes to treat aggressive PCa. Significance Statement The andrographolide analogue, 19-tert-butyldiphenylsilyl-8,7-epoxy andrographolide (3A.1) has shown anticancer activity against metastatic Castration resistance and neuroendocrine variant prostate cancers (mCRPC/NEPC). Additionally, 3A.1 exhibited synergistic anticancer effect in combination with standard therapy docetaxel and cabazitaxel in mCRPC/NEPC. Post-treatment gene expression studies revealed that heat-shock proteins (Hsp70, Hsp40, Hsp27, Hsp90) and MAT2A are major players in the mechanism of 3A.1 action and drug response. Further, DNA damage, cell migration, hypoxia, and autophagy were the crucial pathways for the anticancer activity of 3A.1.
Collapse
|
16
|
Mitra Ghosh T, White J, Davis J, Mazumder S, Kansom T, Skarupa E, Barnett GS, Piazza GA, Bird RC, Mitra AK, Yates C, Cummings BS, Arnold RD. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. Front Pharmacol 2021; 12:736951. [PMID: 34938177 PMCID: PMC8685420 DOI: 10.3389/fphar.2021.736951] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 10/25/2021] [Indexed: 12/11/2022] Open
Abstract
Repetitive, low-dose (metronomic; METRO) drug administration of some anticancer agents can overcome drug resistance and increase drug efficacy in many cancers, but the mechanisms are not understood fully. Previously, we showed that METRO dosing of topotecan (TOPO) is more effective than conventional (CONV) dosing in aggressive human prostate cancer (PCa) cell lines and in mouse tumor xenograft models. To gain mechanistic insights into METRO-TOPO activity, in this study we determined the effect of METRO- and CONV-TOPO treatment in a panel of human PCa cell lines representing castration-sensitive/resistant, androgen receptor (+/−), and those of different ethnicity on cell growth and gene expression. Differentially expressed genes (DEGs) were identified for METRO-TOPO therapy and compared to a PCa patient cohort and The Cancer Genome Atlas (TCGA) database. The top five DEGs were SERPINB5, CDKN1A, TNF, FOS, and ANGPT1. Ingenuity Pathway Analysis predicted several upstream regulators and identified top molecular networks associated with METRO dosing, including tumor suppression, anti-proliferation, angiogenesis, invasion, metastasis, and inflammation. Further, the top DEGs were associated with increase survival of PCa patients (TCGA database), as well as ethnic differences in gene expression patterns in patients and cell lines representing African Americans (AA) and European Americans (EA). Thus, we have identified candidate pharmacogenomic biomarkers and novel pathways associated with METRO-TOPO therapy that will serve as a foundation for further investigation and validation of METRO-TOPO as a novel treatment option for prostate cancers.
Collapse
Affiliation(s)
- Taraswi Mitra Ghosh
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | - Jason White
- Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, United States
| | - Joshua Davis
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | - Suman Mazumder
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
- Center for Pharmacogenomics and Single-Cell Omics, Auburn University, Auburn, AL, United States
| | - Teeratas Kansom
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | - Elena Skarupa
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | - Grafton S. Barnett
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | - Gary A. Piazza
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | - R. Curtis Bird
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States
| | - Amit K. Mitra
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
- Center for Pharmacogenomics and Single-Cell Omics, Auburn University, Auburn, AL, United States
- UAB O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States
| | - Clayton Yates
- Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, United States
- UAB O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States
- Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States
| | - Brian S. Cummings
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, United States
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States
- UAB O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States
- *Correspondence: Robert D. Arnold,
| |
Collapse
|
17
|
Klinczar AM, Griffies JD, Bateman FL, Arnold RD, Jasper SL, Brown AR. Determination of amikacin stability at 1% and 3% concentrations in four topical solutions over a 56 day period. Vet Dermatol 2021; 33:23-e8. [PMID: 34545642 DOI: 10.1111/vde.13025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Anecdotally, amikacin has been added to compounded topical preparations for the management of canine bacterial otitis externa. However, the stability of amikacin within these solutions is unknown. HYPOTHESIS/OBJECTIVES The purpose of this study was to determine the stability of amikacin at 10 and 30 mg/mL concentrations in four topical solutions over a 56 day period. We hypothesised that amikacin would maintain chemical stability within the various solutions. METHODS AND MATERIALS Amikacin was formulated to 10 and 30 mg/mL (1% and 3%) concentrations within four topical solutions: tris-EDTA (TrizEDTA Aqueous Flush) (TE); 0.15% chlorhexidine gluconate and tris-EDTA (TrizCHLOR Flush) (TC); 0.9% NaCl (NA); and 0.9% NaCl + 2 mg/mL dexamethasone (ND). Samples were made in duplicate and stored at room temperature (25°C) for 0, 7,14, 21, 28 and 56 days. Amikacin content was quantified, in triplicate, by ultrahigh-performance liquid chromatography tandem mass spectrometry. RESULTS The recovered amikacin concentrations for the 10 mg/mL solutions ranged from 10 to 13.5 mg/mL (mean 11.5 mg/mL) with the exception of NA sample 2 at Day (D)0 (9.4 mg/mL) and D7 (9.2 mg/mL). The recovered amikacin concentrations for the 30 mg/mL solutions ranged from 30 to 40.2 mg/mL (mean 35.7 mg/mL). No significant difference was seen between the amikacin concentrations at D0 compared to D56 for all solutions except 10 mg/mL TE (P < 0.001). CONCLUSIONS AND CLINICAL RELEVANCE Amikacin maintained stability within TE, TC, NA and ND over 56 days except when formulated at 10 mg/mL within TE.
Collapse
Affiliation(s)
| | | | | | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, 257 Pharmacy Research Building, Auburn, AL, 36849, USA
| | - Shanese L Jasper
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, 257 Pharmacy Research Building, Auburn, AL, 36849, USA
| | - Austin R Brown
- Department of Statistics and Analytical Sciences, Kennesaw State University, 257 Kennesaw State Univ Rd NW, Kennesaw, GA, 30144, USA
| |
Collapse
|
18
|
Osburn SC, Roberson PA, Medler JA, Shake J, Arnold RD, Alamdari N, Bucci LR, Vance A, Sharafi M, Young KC, Roberts MD. Effects of 12-Week Multivitamin and Omega-3 Supplementation on Micronutrient Levels and Red Blood Cell Fatty Acids in Pre-menopausal Women. Front Nutr 2021; 8:610382. [PMID: 34327207 PMCID: PMC8313763 DOI: 10.3389/fnut.2021.610382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 06/11/2021] [Indexed: 11/13/2022] Open
Abstract
The purpose of this study was to validate the efficacy of a customized vitamin-mineral supplement on blood biomarkers in pre-menopausal females. Women (21-40 years old) who were apparently healthy were recruited from the local community (ClinicalTrials.gov trial registration NCT03828097). Pretesting (PRE) occurred in the morning 5 ± 2 days following each participant's menses and involved a fasted blood draw, body mass assessment, and blood pressure assessment. Participants were then randomly assigned in a double-blinded fashion to either the multivitamins (MV) (n = 43) or placebo group (n = 51). Participants consumed two capsules per day with breakfast for 12 weeks. Following the trial, participants reported to the laboratory for POST assessments, which replicated PRE procedures. Red blood cell fatty acid and serum micronutrient analyses were performed in a blinded fashion at hematology laboratories. A group × time interaction was observed for serum vitamin D levels (p < 0.001). MV increased levels from PRE to POST (+43.7%, p < 0.001), whereas no change occurred in the placebo group. Additionally, 78% of MV participants at PRE exhibited inadequate vitamin D levels (<40 ng/dl), whereas only 30% exhibited levels below this threshold at POST. An interaction was also observed for serum folate levels (p < 0.001). MV increased serum folate from PRE to POST (p < 0.001), whereas no change occurred in the placebo group. Red blood cell omega-3 fatty acid content increased from PRE to POST in the MV group (p < 0.001) and placebo group (p < 0.05), although POST values were greater in the MV group (p < 0.001). An interaction was observed for serum HDL cholesterol levels (p = 0.047), and a non-significant increase in this variable from PRE to POST occurred in the MV group (p = 0.060). Four-day food recalls indicated MV increased intake of omega-3 fatty acids, vitamin D, folate, and other micronutrients. In summary, MV supplementation increased serum vitamin D, serum folate, and red blood cell omega-3 fatty acid levels. However, these data are limited to healthy females, and more research is needed to examine if MV can affect metabolic disturbances in individuals with micronutrient deficiencies.
Collapse
Affiliation(s)
- Shelby C Osburn
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Paul A Roberson
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Jessica A Medler
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Jacob Shake
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Robert D Arnold
- Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | | | | | | | | | - Kaelin C Young
- School of Kinesiology, Auburn University, Auburn, AL, United States.,Cell Biology and Physiology, Edward via College of Osteopathic Medicine, Auburn, AL, United States
| | - Michael D Roberts
- School of Kinesiology, Auburn University, Auburn, AL, United States.,Cell Biology and Physiology, Edward via College of Osteopathic Medicine, Auburn, AL, United States
| |
Collapse
|
19
|
Alhowail AH, Pinky PD, Eggert M, Bloemer J, Woodie LN, Buabeid MA, Bhattacharya S, Jasper SL, Bhattacharya D, Dhanasekaran M, Escobar M, Arnold RD, Suppiramaniam V. Doxorubicin induces dysregulation of AMPA receptor and impairs hippocampal synaptic plasticity leading to learning and memory deficits. Heliyon 2021; 7:e07456. [PMID: 34296005 PMCID: PMC8282984 DOI: 10.1016/j.heliyon.2021.e07456] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 06/10/2021] [Accepted: 06/28/2021] [Indexed: 11/27/2022] Open
Abstract
Doxorubicin (Dox) is a chemotherapeutic agent used widely to treat a variety of malignant cancers. However, Dox chemotherapy is associated with several adverse effects, including "chemobrain," the observation that cancer patients exhibit through learning and memory difficulties extending even beyond treatment. This study investigated the effect of Dox treatment on learning and memory as well as hippocampal synaptic plasticity. Dox-treated mice (5 mg/kg weekly x 5) demonstrated impaired performance in the Y-maze spatial memory task and a significant reduction in hippocampal long-term potentiation. The deficit in synaptic plasticity was mirrored by deficits in the functionality of synaptic `α-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) channels, including reduced probability of opening, decreased dwell open time, and increased closed times. Furthermore, a reduction in the AMPAR subunit GluA1 level, its downstream signaling molecule Ca2+/calmodulin-dependent protein kinase (CaMKII), and brain-derived neurotrophic factor (BDNF) were observed. This was also accompanied by an increase in extracellular signal regulated kinase (ERK) and protein kinase B (AKT) activation. Together these data suggest that Dox-induced cognitive impairments are at least partially due to alterations in the expression and functionality of the glutamatergic AMPAR system.
Collapse
Affiliation(s)
- Ahmad H. Alhowail
- Department of Pharmacology and Toxicology, Qassim University, Buraydah, Saudi Arabia
| | - Priyanka D. Pinky
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
| | - Matthew Eggert
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
| | - Jenna Bloemer
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
- Department of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, New York, NY, USA
| | - Lauren N. Woodie
- Department of Nutrition, Dietetics and Hospitality Management, College of Human Sciences, Auburn University, Auburn, Alabama, USA
- Institute for Diabetes, Obesity and Metabolism, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Manal A. Buabeid
- College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
| | - Subhrajit Bhattacharya
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, USA
| | - Shanese L. Jasper
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
| | | | - Muralikrishnan Dhanasekaran
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, USA
| | - Martha Escobar
- Department of Psychology, Oakland University, Rochester, MI, USA
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, USA
| | - Vishnu Suppiramaniam
- Department of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA
- Center for Neuroscience Initiative, Auburn University, Auburn, AL, USA
| |
Collapse
|
20
|
Annaji M, Poudel I, Boddu SHS, Arnold RD, Tiwari AK, Babu RJ. Resveratrol-loaded nanomedicines for cancer applications. Cancer Rep (Hoboken) 2021; 4:e1353. [PMID: 33655717 PMCID: PMC8222557 DOI: 10.1002/cnr2.1353] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/16/2020] [Accepted: 01/04/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Resveratrol (3, 5, 4' -trihydroxystilbene), a natural polyphenol and phytoalexin, has drawn considerable attention in the past decade due to its wide variety of therapeutic activities such as anticancer, anti-inflammatory, and antioxidant properties. However, its poor water solubility, low chemical stability, and short biological half-life limit its clinical utility. RECENT FINDINGS Nanoparticles overcome the limitations associated with conventional chemotherapeutic drugs, such as limited availability of drugs to the tumor tissues, high systemic exposures, and consequent toxicity to healthy tissues. This review focuses on the physicochemical properties of resveratrol, the therapeutic potential of resveratrol nano-formulations, and the anticancer activity of resveratrol encapsulated nanoparticles on various malignancies such as skin, breast, prostate, colon, liver, ovarian, and lung cancers (focusing on both in vitro and in vivo studies). CONCLUSIONS Nanotechnology approaches have been extensively utilized to achieve higher solubility, improved oral bioavailability, enhanced stability, and controlled release of resveratrol. The resveratrol nanoparticles have markedly enhanced its anticancer activity both in vitro and in vivo, thus considering it as a potential strategy to fight various cancers.
Collapse
Affiliation(s)
- Manjusha Annaji
- Department of Drug Discovery and DevelopmentAuburn UniversityAuburnAlabamaUSA
| | - Ishwor Poudel
- Department of Drug Discovery and DevelopmentAuburn UniversityAuburnAlabamaUSA
| | - Sai H. S. Boddu
- Department of Pharmaceutical Sciences, College of Pharmacy and Health SciencesAjman UniversityAjmanUnited Arab Emirates
| | - Robert D. Arnold
- Department of Drug Discovery and DevelopmentAuburn UniversityAuburnAlabamaUSA
| | - Amit K. Tiwari
- Department of Pharmacology and Experimental Therapeutics, College of Pharmacy & Pharmaceutical SciencesUniversity of ToledoToledoOhioUSA
| | - R. Jayachandra Babu
- Department of Drug Discovery and DevelopmentAuburn UniversityAuburnAlabamaUSA
| |
Collapse
|
21
|
Frugé AD, Smith KS, Riviere AJ, Tenpenny-Chigas R, Demark-Wahnefried W, Arthur AE, Murrah WM, van der Pol WJ, Jasper SL, Morrow CD, Arnold RD, Braxton-Lloyd K. A Dietary Intervention High in Green Leafy Vegetables Reduces Oxidative DNA Damage in Adults at Increased Risk of Colorectal Cancer: Biological Outcomes of the Randomized Controlled Meat and Three Greens (M3G) Feasibility Trial. Nutrients 2021; 13:nu13041220. [PMID: 33917165 PMCID: PMC8067874 DOI: 10.3390/nu13041220] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 04/03/2021] [Accepted: 04/05/2021] [Indexed: 12/24/2022] Open
Abstract
Green leafy vegetables (GLV) may reduce the risk of red meat (RM)-induced colonic DNA damage and colorectal cancer (CRC). We previously reported the primary outcomes (feasibility) of a 12-week randomized controlled crossover trial in adults with habitual high RM and low GLV intake with body mass index (BMI) > 30 kg/m2 (NCT03582306). Herein, our objective was to report a priori secondary outcomes. Participants were recruited and enrolled in 2018, stratified by gender, and randomized to two arms: immediate intervention group (IG, n = 26) or delayed intervention group (DG, n = 24). During the 4 week intervention period, participants were provided with frozen GLV and counseled to consume 1 cooked cup equivalent daily. Participants consumed their normal diet for the remaining 8 weeks. At each of four study visits, anthropometrics, stool, and blood were taken. Overall, plasma Vitamin K1 (0.50 ± 1.18 ng/mL, p < 0.001) increased, while circulating 8OHdG (−8.52 ± 19.05 ng/mL, p < 0.001), fecal 8OHdG (−6.78 ± 34.86 ng/mL, p < 0.001), and TNFα (−16.95 ± 60.82 pg/mL, p < 0.001) decreased during the GLV intervention compared to control periods. Alpha diversity of fecal microbiota and relative abundance of major taxa did not differ systematically across study periods. Further investigation of the effects of increased GLV intake on CRC risk is warranted.
Collapse
Affiliation(s)
- Andrew D. Frugé
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL 36849, USA; (K.S.S.); (A.J.R.); (R.T.-C.)
- Correspondence: ; Tel.: +334-844-3271
| | - Kristen S. Smith
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL 36849, USA; (K.S.S.); (A.J.R.); (R.T.-C.)
| | - Aaron J. Riviere
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL 36849, USA; (K.S.S.); (A.J.R.); (R.T.-C.)
| | - Rachel Tenpenny-Chigas
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL 36849, USA; (K.S.S.); (A.J.R.); (R.T.-C.)
| | - Wendy Demark-Wahnefried
- Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA;
| | - Anna E. Arthur
- Department of Food Science and Human Nutrition, Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Champaign, IL 61801, USA;
| | - William M. Murrah
- Department of Educational Foundations, Leadership, and Technology, Auburn University, Auburn, AL 36849, USA;
| | - William J. van der Pol
- Department of Computational Biology and Bioinformatics, University of Alabama at Birmingham, Birmingham, AL 35294, USA;
| | - Shanese L. Jasper
- Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA;
| | - Casey D. Morrow
- Department of Drug Discovery and Development, Auburn University Harrison School of Pharmacy, Auburn, AL 36849, USA; (C.D.M.); (R.D.A.)
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Auburn University Harrison School of Pharmacy, Auburn, AL 36849, USA; (C.D.M.); (R.D.A.)
| | - Kimberly Braxton-Lloyd
- Department of Pharmacy Services, Auburn University Harrison School of Pharmacy, Auburn, AL 36849, USA;
| |
Collapse
|
22
|
Kurakula M, Chen L, Tiwari AK, Srinivas NR, Dash RP, Panizzi PR, Arnold RD, Babu RJ. Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy. Crit Rev Ther Drug Carrier Syst 2021; 38:1-38. [PMID: 34369738 DOI: 10.1615/critrevtherdrugcarriersyst.2021034903] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Melanoma is one of the most aggressive forms of cancer with limited treatment options available. Successful treatment involves a combination of surgical resection of the tumor; chemotherapy and immunotherapy. Given their complex nature, the rapid development of drug resistance and metastatic spread, nanotechnology-based therapeutics are an attractive option for effective melanoma treatment. Nano-vesicular-based delivery systems hold the promise of aiding in the diagnosis and treatment of melanoma. These formulations can improve targeted delivery, deliver insoluble drugs belonging to class II, biopharmaceutical classification system, and alter drug pharmacokinetics and exposure profiles. These nanometer-sized carriers predominantly bypass the reticuloendothelial system and, thereby, improve blood circulation time and enhance tumor cell uptake with reduced toxicity. In this review, various lipid-based nano-formulations used in the diagnosis, treatment, or both for melanoma are discussed. Utilization of these na-no-formulations with a single drug or a combination of drugs, nucleic acid-based compounds (small interfering RNA, DNA) and targeting antibodies as other possibilities for melanoma are reviewed. We also present a state-of-the-art overview of alternative therapeutic approaches for the treatment of melanoma, such as photodynamic, immune, and gene therapies.
Collapse
Affiliation(s)
- Mallesh Kurakula
- Department of Biomedical Engineering, The University of Memphis, Memphis, TN 38152, USA
| | - Li Chen
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Amit K Tiwari
- Department of Pharmacology and Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA
| | | | - Ranjeet Prasad Dash
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA; ADME-DMPK, Charles River Laboratories, Ashland, OH 44805, USA
| | - Peter R Panizzi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - R Jayachandra Babu
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| |
Collapse
|
23
|
Abstract
The field of nanotechnology has grown over the last two decades and made the transition from the benchtop to applied technologies. Nanoscale-sized particles, or nanoparticles, have emerged as promising tools with broad applications in drug delivery, diagnostics, cosmetics and several other biological and non-biological areas. These advances lead to questions about nanoparticle safety. Despite considerable efforts to understand the toxicity and safety of these nanoparticles, many of these questions are not yet fully answered. Nevertheless, these efforts have identified several approaches to minimize and prevent nanoparticle toxicity to promote safer nanotechnology. This review summarizes our current knowledge on nanoparticles, their toxic effects, their interactions with mammalian cells and finally current approaches to minimizing their toxicity.
Collapse
Affiliation(s)
- Wided Najahi-Missaoui
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA;
- Correspondence: ; Tel.: +1-706-542-6552; Fax: +70-6542-5358
| | - Robert D. Arnold
- Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA;
- Interdisciplinary Toxicology Program, University of Georgia, Athens, GA 30602, USA
| | - Brian S. Cummings
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA;
- Interdisciplinary Toxicology Program, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
24
|
Al Saqr A, Aldawsari MF, Alrbyawi H, Poudel I, Annaji M, Mulabagal V, Ramani MV, Gottumukkala S, Tiwari AK, Dhanasekaran M, Panizzi PR, Arnold RD, Babu RJ. Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells. AAPS PharmSciTech 2020; 21:304. [PMID: 33150503 DOI: 10.1208/s12249-020-01846-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 10/07/2020] [Indexed: 12/20/2022] Open
Abstract
Hispolon is a small molecular weight polyphenol that has antioxidant, anti-inflammatory, and anti-proliferative activities. Our recent study has demonstrated hispolon as a potent apoptosis inducer in melanoma cell lines. Doxorubicin is a broad spectrum first-line treatment for various kinds of cancers. In this study, co-delivery of doxorubicin and hispolon using a liposomal system in B16BL6 melanoma cell lines for synergistic cytotoxic effects was investigated. Liposomes were prepared using a lipid film hydration method and loaded with doxorubicin or hispolon. The formulations were characterized for particle size distribution, release profile, and encapsulation efficiency (EE). In addition, in vitro cytotoxicity, in vitro cell apoptosis, and cellular uptake were evaluated. Liposomes exhibited small particle size (mean diameter ~ 100 nm) and narrow size distribution (polydispersity index (< 0.2) and high drug EE% (> 90%). The release from liposomes showed slower release compared to free drug solution as an additional time required for the release of drug from the liposome lipid bilayer. Liposome loaded with doxorubicin or hispolon exhibited significantly higher cytotoxicity against B16BL6 melanoma cells as compared to doxorubicin solution or hispolon solution. Likewise, co-delivery of hispolon and doxorubicin liposomes showed two-fold and three-fold higher cytotoxicity, as compared to hispolon liposomes or doxorubicin liposomes, respectively. In addition, co-delivery of doxorubicin and hispolon in liposomes enhanced apoptosis more than the individual drugs in the liposome formulation. In conclusion, the co-delivery of hispolon and doxorubicin could be a promising therapeutic approach to improve clinical outcomes against melanoma.
Collapse
|
25
|
Vazquez Fuster IB, Taylor AR, Smith AN, Duran SH, Ravis WR, Jasper SL, Arnold RD. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs. J Vet Intern Med 2020; 34:1563-1569. [PMID: 32442344 PMCID: PMC7379012 DOI: 10.1111/jvim.15809] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 04/23/2020] [Accepted: 05/06/2020] [Indexed: 01/02/2023] Open
Abstract
Background Prolonged cytotoxic concentrations of cytarabine (CA) are required for maximum cytotoxicity. DepoCyt is a human liposomal cytarabine (LC) product that lasts longer in plasma and CSF compared with free CA (FC). The use of LC has not been evaluated in dogs. Objectives To perform a LC pharmacokinetic (PK) study when administered SC in dogs. Animals Five healthy female beagles. Methods Three‐period, 3‐treatment, nonblinded, randomized, and crossover design, including a pilot study. LC was administered at 50 mg/m2 SC and FC was administered at 25 and 50 mg/m2 SC and IV. Plasma CA concentrations were measured until 240, 72, and 8 hours after SC LC, SC FC, and IV FC administration, respectively. CA plasma concentrations were quantitated by ultra‐high‐performance liquid chromatography with mass spectrometry (MS/MS) detection and concentration‐time profiles were evaluated by noncompartmental analysis. Results Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration‐time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%. The PK profiles of FC after SC and IV administration differed when compared with LC. Conclusions and Clinical Importance In healthy dogs, SC LC administration at 50 mg/m2 results in measurable plasma CA concentrations, is apparently safe and well tolerated, but does not result in prolonged cytotoxic plasma concentrations. Poor absorption of LC prevented establishment of a complete LC PK profile.
Collapse
Affiliation(s)
| | - Amanda R Taylor
- Department of Neurology, MedVet Columbus, Worthington, Ohio, USA
| | - Annette N Smith
- Department of Clinical Sciences, Wilford and Kate Bailey Small Animal Teaching Hospital, Auburn University College of Veterinary Medicine, Auburn, Alabama, USA
| | - Sue H Duran
- J.T. Vaughan Large Animal Teaching Hospital, Auburn University College of Veterinary Medicine, Auburn, Alabama, USA
| | - William R Ravis
- Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA
| | - Shanese L Jasper
- Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA
| | - Robert D Arnold
- Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA
| |
Collapse
|
26
|
Al Saqr A, Majrashi M, Alrbyawi H, Govindarajulu M, Fujihashi A, Gottumukkala S, Poudel I, Arnold RD, Babu RJ, Dhanasekaran M. Elucidating the anti-melanoma effect and mechanisms of Hispolon. Life Sci 2020; 256:117702. [PMID: 32387411 DOI: 10.1016/j.lfs.2020.117702] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/11/2020] [Accepted: 04/14/2020] [Indexed: 02/06/2023]
Abstract
There is a rapid increase in the incidence of melanoma which has led to a global crisis. Thus, there is a great need for developing novel, safe and effective drugs for the treatment of melanoma. Hispolon is a small molecular weight polyphenol derived from Phellinus linteus, which has antioxidant, anti-inflammatory and anti-proliferative activities. Hispolon has been reported to induce apoptosis in gastric cancer, hepatocellular carcinoma, and myeloid leukemia. However, the anticancer effect in melanoma is not well elucidated. Thus, our present study was to investigate the anti-cancer effect of hispolon on melanoma cancer cells. B16BL6 cells were treated with different concentrations of hispolon for 24 h and the effect on oxidative stress, mitochondrial functions, apoptosis and cell proliferation were studied. Hispolon is a potent generator of reactive oxygen species, nitrite and lipid peroxide levels. Furthermore, it significantly inhibits the expression of Bcl-2 and promotes the expression of Bax, increases the activity of caspase 1 and 3, inhibits mitochondrial Complex I and IV activities. By the above mechanisms, hispolon dose-dependently exhibited the antimelanoma effect similar to the well established pharmacological agent, curcumin. Thus, hispolon can be a potent anti-melanoma drug in the future if the pharmacodynamic effects and the toxicological studies are appropriately carried out.
Collapse
Affiliation(s)
- Ahmed Al Saqr
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia
| | - Mohammed Majrashi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849; Department of Pharmacology, Faculty of Medicine, University of Jeddah, Saudi Arabia
| | - Hamad Alrbyawi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849; Pharmaceutics and Pharmaceutical Technology Department, College of Pharmacy, Taibah University, Saudi Arabia
| | - Manoj Govindarajulu
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849
| | - Ayaka Fujihashi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849
| | | | - Ishwor Poudel
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849
| | - R Jayachandra Babu
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL 36849.
| | | |
Collapse
|
27
|
Alrbyawi H, Poudel I, Dash RP, Srinivas NR, Tiwari AK, Arnold RD, Babu RJ. Role of Ceramides in Drug Delivery. AAPS PharmSciTech 2019; 20:287. [PMID: 31410612 DOI: 10.1208/s12249-019-1497-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 07/31/2019] [Indexed: 12/20/2022] Open
Abstract
Ceramides belong to the sphingolipid group of lipids, which serve as both intracellular and intercellular messengers and as regulatory molecules that play essential roles in signal transduction, inflammation, angiogenesis, and metabolic disorders such as diabetes, neurodegenerative diseases, and cancer cell degeneration. Ceramides also play an important structural role in cell membranes by increasing their rigidity, creating micro-domains (rafts and caveolae), and altering membrane permeability; all these events are involved in the cell signaling. Ceramides constitute approximately half of the lipid composition in the human skin contributing to barrier function as well as epidermal signaling as they affect both proliferation and apoptosis of keratinocytes. Incorporation of ceramides in topical preparations as functional lipids appears to alter skin barrier functions. Ceramides also appear to enhance the bioavailability of drugs by acting as lipid delivery systems. They appear to regulate the ocular inflammation signaling, and external ceramides have shown relief in the anterior and posterior eye disorders. Ceramides play a structural role in liposome formulations and enhance the cellular uptake of amphiphilic drugs, such as chemotherapies. This review presents an overview of the various biological functions of ceramides, and their utility in topical, oral, ocular, and chemotherapeutic drug delivery.
Collapse
|
28
|
Quach ND, Kaur SP, Eggert MW, Ingram L, Ghosh D, Sheth S, Nagy T, Dawson MR, Arnold RD, Cummings BS. Paradoxical Role of Glypican-1 in Prostate Cancer Cell and Tumor Growth. Sci Rep 2019; 9:11478. [PMID: 31391540 PMCID: PMC6685992 DOI: 10.1038/s41598-019-47874-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Accepted: 07/25/2019] [Indexed: 02/07/2023] Open
Abstract
Recent studies suggest that glypican-1 (GPC-1) is a biomarker for prostate cancer, but there are few studies elucidating the role of GPC-1 in prostate cancer progression. We observed high expression of GPC-1 in more aggressive prostate cancer cell lines such as PC-3 and DU-145. While inhibition of GPC-1 expression in PC-3 cells decreased cell growth and migration in vitro, it surprisingly increased cell proliferation and migration in DU-145 cells, suggesting that the role of GPC-1 is cell type-dependent. Further, GPC-1 inhibition increased PC-3 tumor size in NCr nude mice xenografts. We hypothesized that the discrepancy between the in vitro and in vivo data is mediated by stromal cells in the tumor microenvironment. Thus, we tested the effect of tumor conditioned media (TCM) on gene expression in human mesenchymal stem cells and fibroblasts. Treatment of stromal cells with TCM from PC-3 cells transfected with GPC-1 shRNA increased the expression of migration markers, endocrine/paracrine biomolecules, and extracellular matrix components. Additionally, the decreased cell growth in GPC-1 knockdown PC-3 cells was rescued by coculturing with stromal cells. These data demonstrate the paradoxical role that GPC-1 plays in prostate cancer cell growth by interacting with stromal cells and through ECM remodeling and endocrine/paracrine signaling.
Collapse
Affiliation(s)
- Nhat D Quach
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA.,Department of Molecular Pharmacology, Physiology, & Biotechnology, Brown University, Providence, RI, USA
| | - Sukhneeraj Pal Kaur
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA
| | - Matthew W Eggert
- Department of Drug Discovery & Development, Auburn University, Auburn, AL, USA
| | - Lishann Ingram
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA
| | - Deepraj Ghosh
- Department of Molecular Pharmacology, Physiology, & Biotechnology, Brown University, Providence, RI, USA
| | - Sheela Sheth
- Medical College of Georgia, Augusta University, Augusta, GA, USA
| | - Tamas Nagy
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Michelle R Dawson
- Department of Molecular Pharmacology, Physiology, & Biotechnology, Brown University, Providence, RI, USA.,Center for Biomedical Engineering, Brown University, Providence, RI, USA.,School of Engineering, Brown University, Providence, RI, USA
| | - Robert D Arnold
- Department of Drug Discovery & Development, Auburn University, Auburn, AL, USA.,Interdisciplinary Toxicology Program, University of Georgia, Athens, GA, USA
| | - Brian S Cummings
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA. .,Interdisciplinary Toxicology Program, University of Georgia, Athens, GA, USA.
| |
Collapse
|
29
|
Kaur SP, Lee HK, Arnold RD, Cummings BS. Abstract 1913: Role of glypican 1 in regulating fibroblast activation in the prostate cancer tumor microenvironment. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer is a heterogeneous collection of neoplastic cells, surrounded by non-malignant, stromal cells, and extracellular matrix (ECM), among other constituents. Cross-talk between tumor and stromal cells forms a dynamic tumor microenvironment (TME) that mediates cell growth, proliferation, and metastasis. The TME can inhibit cancer growth and proliferation during the initial stages of carcinogenesis; however, cancer cells can evade these inhibitory signals, and reshape the TME, making it more amenable to their own growth. This gives rise to cancer-associated stromal cells, including cancer-associated fibroblasts (CAFs). CAFs further modulate the TME by regulating the release of growth signals, cell death, ECM remodeling, angiogenesis, and epithelial-mesenchymal transition. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan (HSPG) that has both pro-mitogenic and pro-metastatic activity. GPC1’s role in regulating fibroblasts and their transformation into CAFs has not been investigated. We studied the ability of prostate cancer cells to alter the TME in vitro by exposing human bone fibroblasts (HS-5 cells) to tumor conditioned media (TCM) isolated from a human neuroendocrine (DU-145) and bone (PC-3) metastatic prostate cancer cell lines and assessed changes in cell morphology and cytotoxicity (using MTT). Exposure of HS-5 cells to TCM from DU-145 and PC-3 cells altered cellular morphology to a more mesenchymal phenotype similar to that seen in active myofibroblasts. TCM also decreased MTT staining in a time-dependent manner. We also determined the effect of GPC1 knockdown (KD) in HS-5 cells on cell morphology, migration and cytotoxicity. Interestingly, we saw phenotypic switching of GPC1 KD HS-5 cells to a myofibroblast like morphology akin to that when treated with TCM. There was no change in cytotoxicity in GPC1 KD HS-5 cells as compared to control cells. However, GPC1 KD enhanced the migration of HS-5 cells in wound healing assay. Migration was also increased in GPC1 KD HS-5 cells upon treatment with TCM. GPC1 KD also increased HS-5 cell contractility significantly. Collectively, these data support the hypothesis that GPC1 plays an inhibitory role in the TME of prostate cancer by regulating the activation of fibroblasts.
Citation Format: Sukhneeraj P. Kaur, Hee K. Lee, Robert D. Arnold, Brian S. Cummings. Role of glypican 1 in regulating fibroblast activation in the prostate cancer tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1913.
Collapse
|
30
|
Alnaim AS, Eggert MW, Nie B, Quanch ND, Jasper SL, Davis J, Barnett GS, Cummings BS, Panizzi PR, Arnold RD. Abstract 2985: Identifying uptake and biodistribution of liposome nanoparticles associated with secretes phospholipase A2 proteins and PLA2 receptors within a prostate cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Exploiting differences in tumor pathophysiology can enhance the delivery and antitumor activity of chemotherapeutics encapsulated in drug carriers. Long-circulating nanoparticle drug carriers, such as pegylated-sterically-stabilized liposomes (SSL), can stably entrap drug, alter drug disposition, improve antitumor activity and minimize toxicity. However, control of their drug-release kinetics has limited their clinical potential. Secretory phospholipases A2 (sPLA2) are excreted and over expressed in a variety of tumors, e.g., up to 22-fold in prostate. These enzymes degrade phospholipids preferentially and have been hypothesized as targets to control drug release from lipid-based nanoparticles, such as liposomes. While they have shown activity in preclinical models, the clinical performance of these formulations has been limited. The goal of these studies was to gain insights into how sPLA2-targeted liposome formulation (SPRL) alter drug release and uptake, specifically examining the role of sPLA2 and its membrane receptor (PLA2R1). Studies were performed using a metastatic-derived human prostate adenocarcinoma cells (PC-3) and a PLA2R1 knock-down variant (PC-3-PLA2R-KD) while varying supplementation of sPLA2 enzyme isoforms (IIA, X, V). Liposomes (SSL & SPRL) were made as described previously and included DiR, a non-exchangeable near-infrared fluorescent dye. In vitro uptake and deposition of
various formulations was determined using flow cytometry and fluorescence microscopy by measuring DiR and doxorubicin (fluorescent anticancer agent) entrapped within some of the formulations. Biodistribution and circulation times were determined non-invasively on an IVIS Lumina XRMS and iThera Multispectral Optoacoustic Tomography (MSOT) systems in Athymic mouse xenograft models of prostate cancer. Liposomes formulations, SPRL and SSL were 120±1 and 118±2 nm. Circulation half-life and tumor deposition was similar for both formulations, suggesting the enhanced pharmacological activity is related to release/uptake after drug extravasation.. In-vitro studies showed that PC-3-PLA2R-KD cells had greater DiR fluorescence of both formulations than wild PC-3 after 48 hr. Moreover, SPRL had greater uptake than SSL formulation (p<0.05) beyond 24 hr. In-vivo studies showed greater uptake of SSL and SPRL in the PC-3-PLA2R-KD tumors. Overall these data suggest that PLA2R1 plays an important role in the performance of SSL and SPRL formulations. Further studies are needed to gain insights into the clinical significance and to determine if presence of PLA2R1 can be used to identify specific patient populations that would respond to treatment with SPRL.
Citation Format: Ahmed S. Alnaim, Matthew W. Eggert, Ben Nie, Nhat D. Quanch, Shanese L. Jasper, Joshua Davis, Grafton S. Barnett, Brian S. Cummings, Peter R. Panizzi, Robert D. Arnold. Identifying uptake and biodistribution of liposome nanoparticles associated with secretes phospholipase A2 proteins and PLA2 receptors within a prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2985.
Collapse
Affiliation(s)
| | | | - Ben Nie
- 1Auburn University, Auburn, AL
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Ghosh TM, Davis J, Barnett GS, Skarupa E, Warner JD, Cummings BS, Arnold RD. Abstract 2944: Identification of key transcriptomic and epigenomic factors influencing conventional and metronomic dosing in aggressive and non-aggressive prostate cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Repetitive, low-dose drug administration (metronomic; METRO) shows ability to overcome drug resistance and increased drug efficacy in many cancers, but the mechanisms are not understood fully. Previously we showed topotecan (TOPO) METRO dosing was more effective than conventional (CONV) dosing in aggressive prostate cancer cell lines and xenograft mouse models. To explore possible mechanisms by which METRO dosing alters tumor growth and metastases, we performed targeted mRNA and miRNA expression studies and identified potential candidate cancer pathway genes and miRNA-mRNA pairs as unique treatment-related biomarkers for alternative TOPO-METRO therapy. To determine drug response, Androgen-independent human prostate cancer cells (PC3), androgen-dependent (LNCaP) cell lines were treated with TOPO following CONV and METRO dosing schedules. Cancer pathway gene and micro-RNA expression profiles were assessed at the calculated IC50 of TOPO after each treatment. Expression signatures were identified using differential expression (DE) analysis software and a Spearman’s rank-based correlation was used to assess the association of drug response, mRNA and miRNA expression. Gene signatures associated with TOPO-METRO therapy were validated against patient profiles in The Cancer Genome Atlas (TCGA) and Genomic Data Commons (GDC) and protein expression of most significant genes by immunoblotting. We identified disparate treatment-related mRNA and miRNA expression signatures for TOPO-METRO vs CONV treatment. We also identified a gene signature (top five gene: SERPINB5, CDKN1A, TNF, FOS, & ANGPT1) for both PC-3 and LNCaP following TOPO-METRO dosing. Ingenuity Pathway Analysis identified that upregulation of tumor suppressor, anti-proliferative genes (eg, SERPINB5), genes involved in activation of the immune system (RPL13A) and down regulation of genes involved in apoptosis, invasion, metastasis, and inflammation (TNF, FOS, and MMP1) are likely vital to the observed treatment response. Epigenetic analysis showed distinct miRNA expression changes may influence differential gene expression (miRNA-mRNA pairs) for TOPO-METRO dosing. 20 miRNAs genes (including miR-30c, miR-19a, mir-20a, mir-17, let7i & let7b) were associated with TOPO cytotoxicity (p<0.05); seven of these bind to 28 mRNAs (p<0.05) as mRNA-miRNA pairs. Furthermore, we confirmed the top 5 significant genes (e.g. FOS, SERPINEB5, MMP9) for TOPO-Metro therapy by in-silico validation (TCGA). Overall, these studies address a fundamental gap in knowledge related to the effect of METRO dosing on genomic and epigenetic influences and overall treatment efficacy. Using genomics, transcriptomics and epigenomics approaches we determined gene signatures that may be used in identifying patients and personalizing their treatment with the goal of improving overall survival.
Citation Format: Taraswi Mitra Ghosh, Joshua Davis, Grafton S. Barnett, Elena Skarupa, Jeff D. Warner, Brian S. Cummings, Robert D. Arnold. Identification of key transcriptomic and epigenomic factors influencing conventional and metronomic dosing in aggressive and non-aggressive prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2944.
Collapse
|
32
|
Habbit NL, Anbiah B, Anderson LS, Suresh J, Hassani I, Eggert M, Jasper SL, Prabhakarpandian B, Arnold RD, Lipke EA. Abstract 1915: In vivo prostate tumor tissue stiffness differs by tumor region and can be recapitulated in bioengineered prostate tumor tissues. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Throughout the tumorigenic process, locational heterogeneities in tumor tissue microarchitecture develop as a result of aberrant angiogenesis and a subsequently induced oxygen and nutrient gradient within the three-dimensional (3D) mass. This phenomenon often results in differential tissue stiffness between the necrotic, quiescent, and proliferative tumor regions. In vitro, strong correlations have been found to exist between cell culture platform stiffness and acquired chemoresistance and varied drug response. Therefore, to accurately recapitulate the tumor microenvironment, biomimetic models must provide a mechanically similar scaffold. This study reports novel quantification of the in vivo prostate tumor stiffness and the ensuing development of tunable 3D bioengineered tumor tissue (BioTT) to successfully recapitulate in vivo mechanical cues in vitro.
In vivo samples were generated by subcutaneously injecting Matrigel-suspended metastatic prostate cancer cells (PC-3) into the flank of athymic NCr nude mice. Resultant tumors (300 – 1,500 mm3) were excised from the murine host and geometrically dissected to provide samples from the tumor core, midpoint, and periphery. The Young’s modulus was quantified via parallel plate compression under physiological conditions. The 3D BioTT model is comprised of poly(ethylene glycol)-fibrinogen (PF) with varying amounts of excess poly(ethylene glycol) diacrylate (PEGDA) to modulate the mechanical properties of the scaffold. PC-3 cancer cells and BJ-5ta human fibroblasts were encapsulated within the covalently crosslinkable biomaterial and co-cultured for 29 days in vitro. Cell viability was assessed by LIVE/DEAD staining and cellular morphology was visualized with Hoechst 33342, Phalloidin, and the anti-fibroblast immunomarker, TE-7. Temporal variations in cell populations were quantified by flow cytometry and mechanical stiffness characterization was again performed by parallel plate compression.
In vivo prostate cancer tumors presented a wide range of tissue stiffness heterogeneity (200 – 5,750 Pa), characterized by an increasing modulus with respect to locational progression from the core to the periphery (n = 48 per tumor region). The BioTT model successfully recapitulated the full tumor stiffness range through biomaterial composition modulation; the addition of excess PEGDA significantly stiffened the PF scaffold (p ≤ 0.05, n = 3). PC-3 and BJ-5ta cells survived the encapsulation process and remained viable throughout long-term co-culture. Visualization of the 3D cellular microenvironment revealed both cancer and stromal cells maintained characteristic morphology. In future studies, the BioTT will be extended to a microfluidic chip platform, thus augmenting the physiological relevancy of the model by incorporating dynamic shear conditions and the ability to monitor cancer cell metastasis.
Citation Format: Nicole L. Habbit, Benjamin Anbiah, Luke S. Anderson, Joshita Suresh, Iman Hassani, Matthew Eggert, Shanese L. Jasper, Balabhaskar Prabhakarpandian, Robert D. Arnold, Elizabeth A. Lipke. In vivo prostate tumor tissue stiffness differs by tumor region and can be recapitulated in bioengineered prostate tumor tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1915.
Collapse
|
33
|
Jasper SL, Skarupa EB, Cummings BS, Arnold RD. Abstract 991: Secretory phospholipase A2 as a trigger for drug release in the treatment of triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer describes a subgroup of breast cancers which are negative for the estrogen and progesterone receptors as well as the HER2 protein. As such, triple negative breast cancers have seen little benefit from the targeted therapies developed for the treatment of breast cancer. To address this challenge, we examined an alternative target within the tumor as well as the tumor environment. Secretory phospholipase A2 (sPLA2) cleave phospholipids at sn-2 ester bonds, releasing lysophospholipids and fatty acids, and are over expressed in several pathologies including breast cancer. Herein, we evaluated the therapeutic activity of secretory phospholipase A2 responsive liposomes (SPRL) compared to the clinically used, sterically-stabilized, pegylated liposomes (SSL) for in vitro response in a triple-negative breast cancer (TNBC) model. In these studies, SSL and SPRL formulations were made according to previous studies and resulted in three formulations SSL, SPRL- E and SPRL-G. SPRL were made by the addition of either DSPE (SPRL-E) or DSPG (SPRL-G). Doxorubicin was used as the drug of choice and Dox-loaded liposomes were prepared by remote-loading using an ammonium sulfate gradient. Toxicity studies were performed by the use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or resazurin while uptake studies were performed by fluorescence microscopy and flow cytometry. Briefly, cells were seeded at a density of 10,000 cells per well and subjected to free doxorubicin or liposomal doxorubicin in concentrations from 0 - 100 µM. At the appropriate time points, 0-72 hours, cells were harvested for studies. Treatment of breast cancer cells with doxorubicin encapsulated in SSL and SPRL resulted in cytotoxicity in the MDA-MB-231 cells line comparable to free drug with an IC50 of approximately 3 µM at the 72 hour time point. In tracking of drug and liposome delivery, we demonstrated that drug uptake was liposome-dependent, as encapsulation of doxorubicin in SPRL resulted in greater intracellular drug levels compared to SSL. These data show the therapeutic activity of SPRL compared to SSL, and suggest that SPRL may be useful for the treatment of TNBC. Two-dimensional models do not fully recapitulate the complexity of barriers to drug delivery, nor the effect of multiple cell types. Therefore, ongoing studies are examining the utility of these liposome formulations in three-dimensional co-cultures that include macrophages and fibroblasts. In this model, we hope to assess the ability of the tumor microenvironment to alter drug release.
Citation Format: Shanese L. Jasper, Elena B. Skarupa, Brian S. Cummings, Robert D. Arnold. Secretory phospholipase A2 as a trigger for drug release in the treatment of triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 991.
Collapse
|
34
|
Alhowail AH, Bloemer J, Majrashi M, Pinky PD, Bhattacharya S, Yongli Z, Bhattacharya D, Eggert M, Woodie L, Buabeid MA, Johnson N, Broadwater A, Smith B, Dhanasekaran M, Arnold RD, Suppiramaniam V. Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation. Toxicol Mech Methods 2019; 29:457-466. [PMID: 31010378 DOI: 10.1080/15376516.2019.1600086] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Cognitive deficits are commonly reported by patients following treatment with chemotherapeutic agents. Anthracycline-containing chemotherapy regimens are associated with cognitive impairment and reductions in neuronal connectivity in cancer survivors, and doxorubicin (Dox) is a commonly used anthracycline. Although it has been reported that Dox distribution to the central nervous system (CNS) is limited, considerable Dox concentrations are observed in the brain with co-administration of certain medications. Additionally, pro-inflammatory cytokines, which are overproduced in cancer or in response to chemotherapy, can reduce the integrity of the blood-brain barrier (BBB). Therefore, the aim of this study was to evaluate the acute neurotoxic effects of Dox on hippocampal neurons. In this study, we utilized a hippocampal cell line (H19-7/IGF-IR) along with rodent hippocampal slices to evaluate the acute neurotoxic effects of Dox. Hippocampal slices were used to measure long-term potentiation (LTP), and expression of proteins was determined by immunoblotting. Cellular assays for mitochondrial complex activity and lipid peroxidation were also utilized. We observed reduction in LTP in hippocampal slices with Dox. In addition, lipid peroxidation was increased as measured by thiobarbituric acid reactive substances content indicating oxidative stress. Caspase-3 expression was increased indicating an increased propensity for cell death. Finally, the phosphorylation of signaling molecules which modulate LTP including extracellular signal-regulated kinase 1/2 (ERK1/2), p38 mitogen-activated protein kinase, and Akt were increased. This data indicates that acute Dox exposure dose-dependently impairs synaptic processes associated with hippocampal neurotransmission, induces apoptosis, and increases lipid peroxidation leading to neurotoxicity.
Collapse
Affiliation(s)
- Ahmad H Alhowail
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Jenna Bloemer
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Mohammed Majrashi
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Priyanka D Pinky
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | | | - Zhang Yongli
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA.,b Tianjin Huanhu Hospital , Tianjin , PR China
| | - Dwipayan Bhattacharya
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Matthew Eggert
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Lauren Woodie
- c Department of Nutrition, Dietetics and Hospitality Management , College of Human Sciences, Auburn University , Auburn , AL , USA
| | - Manal A Buabeid
- d College of Pharmacy and Health Sciences , Ajman University , Ajman , UAE
| | - Nathaniel Johnson
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Alyssa Broadwater
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Bruce Smith
- e Department of Anatomy, Physiology and Pharmacology , College of Veterinary Medicine, Auburn University , Auburn , AL , USA
| | | | - Robert D Arnold
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| | - Vishnu Suppiramaniam
- a Department of Drug Discovery and Development , Auburn University , Auburn , AL , USA
| |
Collapse
|
35
|
Chen L, Alrbyawi H, Poudel I, Arnold RD, Babu RJ. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines. AAPS PharmSciTech 2019; 20:99. [PMID: 30719596 DOI: 10.1208/s12249-019-1316-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Accepted: 01/22/2019] [Indexed: 02/07/2023] Open
Abstract
This study reports co-delivery of doxorubicin (DOX) and ceramide in a liposomal system in B16BL6 melanoma cell lines for enhanced cytotoxic effects. Different types of ceramides (C6-ceramide, C8-ceramide, and C8-glucosylceramide) and lipids (1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)) were considered in the preparation of liposomes. DOX was encapsulated within liposome, and ceramide was used as the component of the lipid bilayer. The formulations were optimized for size and size distribution, zeta potential, and DOX encapsulation efficiency (EE). Cytotoxic effect on B16BL6 melanoma cell lines was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The ceramide based liposome formulations generally provided a mean diameter < 181 nm, a zeta potential, + 35 mV, and EE > 90% DOX EE. Co-delivery of DOX and C8-ceramide with DOTAP liposomes demonstrated significantly higher cytotoxicity as compared to DOX liposomes without ceramide (P < 0.001), and also showed enhanced cellular uptake by B16BL6 cell lines. This study provides basis for developing a co-delivery system of DOX and ceramide for lowering the dose and dose-related side effects of DOX for the treatment of melanoma.
Collapse
|
36
|
Osekavage KE, Brainard BM, Lane SL, Almoslem M, Arnold RD, Koenig A. Pharmacokinetics of tranexamic acid in healthy dogs and assessment of its antifibrinolytic properties in canine blood. Am J Vet Res 2019; 79:1057-1063. [PMID: 30256146 DOI: 10.2460/ajvr.79.10.1057] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To assess pharmacokinetics of tranexamic acid (TXA) in dogs and assess antifibrinolytic properties of TXA in canine blood by use of a thromboelastography-based in vitro model of hyperfibrinolysis. ANIMALS 6 healthy adult dogs. PROCEDURES Dogs received each of 4 TXA treatments (10 mg/kg, IV; 20 mg/kg, IV; approx 15 mg/kg, PO; and approx 20 mg/kg, PO) in a randomized crossover-design study. Blood samples were collected at baseline (time 0; immediately prior to drug administration) and predetermined time points afterward for pharmacokinetic analysis and pharmacodynamic (thromboelastography) analysis by use of an in vitro hyperfibrinolysis model. RESULTS Maximum amplitude (MA [representing maximum clot strength]) significantly increased from baseline at all time points for all treatments. The MA was lower at 360 minutes for the 10-mg/kg IV treatment than for other treatments. Percentage of clot lysis 30 minutes after MA was detected was significantly decreased from baseline at all time points for all treatments; at 360 minutes, this value was higher for the 10-mg/kg IV treatment than for other treatments and higher for the 20-mg/kg IV treatment than for the 20-mg/kg PO treatment. Maximum plasma TXA concentrations were dose dependent. At 20 mg/kg, IV, plasma TXA concentrations briefly exceeded concentrations suggested for complete inhibition of fibrinolysis. Oral drug administration resulted in a later peak antifibrinolytic effect than did IV administration. CONCLUSIONS AND CLINICAL RELEVANCE Administration of TXA improved clot strength and decreased fibrinolysis in blood samples from healthy dogs in an in vitro hyperfibrinolysis model. Further research is needed to determine clinical effects of TXA in dogs with hyperfibrinolysis.
Collapse
|
37
|
Kephart WC, Wachs TD, Thompson RM, Mobley CB, Fox CD, McDonald JR, Ferguson BS, Young KC, Nie B, Martin JS, Company JM, Pascoe DD, Arnold RD, Moon JR, Roberts MD. Correction to: Ten weeks of branched-chain amino acid supplementation improves select performance and immunological variables in trained cyclists. Amino Acids 2018; 50:1495. [DOI: 10.1007/s00726-018-2632-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Haun CT, Vann CG, Mobley CB, Roberson PA, Osburn SC, Holmes HM, Mumford PM, Romero MA, Young KC, Moon JR, Gladden LB, Arnold RD, Israetel MA, Kirby AN, Roberts MD. Effects of Graded Whey Supplementation During Extreme-Volume Resistance Training. Front Nutr 2018; 5:84. [PMID: 30255024 PMCID: PMC6141782 DOI: 10.3389/fnut.2018.00084] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 08/24/2018] [Indexed: 12/31/2022] Open
Abstract
We examined hypertrophic outcomes of weekly graded whey protein dosing (GWP) vs. whey protein (WP) or maltodextrin (MALTO) dosed once daily during 6 weeks of high-volume resistance training (RT). College-aged resistance-trained males (training age = 5 ± 3 years; mean ± SD) performed 6 weeks of RT wherein frequency was 3 d/week and each session involved 2 upper- and 2 lower-body exercises (10 repetitions/set). Volume increased from 10 sets/exercise (week 1) to 32 sets/exercise (week 6), which is the highest volume investigated in this timeframe. Participants were assigned to WP (25 g/d; n = 10), MALTO (30 g/d; n = 10), or GWP (25–150 g/d from weeks 1–6; n = 11), and supplementation occurred throughout training. Dual-energy x-ray absorptiometry (DXA), vastus lateralis (VL), and biceps brachii ultrasounds for muscle thicknesses, and bioelectrical impedance spectroscopy (BIS) were performed prior to training (PRE) and after weeks 3 (MID) and 6 (POST). VL biopsies were also collected for immunohistochemical staining. The GWP group experienced the greatest PRE to POST reduction in DXA fat mass (FM) (−1.00 kg, p < 0.05), and a robust increase in DXA fat- and bone-free mass [termed lean body mass (LBM) throughout] (+2.93 kg, p < 0.05). However, the MALTO group also experienced a PRE to POST increase in DXA LBM (+2.35 kg, p < 0.05), and the GWP and MALTO groups experienced similar PRE to POST increases in type II muscle fiber cross-sectional area (~+300 μm2). When examining the effects of training on LBM increases (ΔLBM) in all participants combined, PRE to MID (+1.34 kg, p < 0.001) and MID to POST (+0.85 kg, p < 0.001) increases were observed. However, when adjusting ΔLBM for extracellular water (ECW) changes, intending to remove the confounder of edema, a significant increase was observed from PRE to MID (+1.18 kg, p < 0.001) but not MID to POST (+0.25 kg; p = 0.131). Based upon DXA data, GWP supplementation may be a viable strategy to improve body composition during high-volume RT. However, large LBM increases observed in the MALTO group preclude us from suggesting that GWP supplementation is clearly superior in facilitating skeletal muscle hypertrophy. With regard to the implemented RT program, ECW-corrected ΔLBM gains were largely dampened, but still positive, in resistance-trained participants when RT exceeded ~20 sets/exercise/wk.
Collapse
Affiliation(s)
- Cody T Haun
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | | | | | - Paul A Roberson
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Shelby C Osburn
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Hudson M Holmes
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Petey M Mumford
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Matthew A Romero
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Kaelin C Young
- School of Kinesiology, Auburn University, Auburn, AL, United States.,Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine-Auburn Campus, Auburn, AL, United States
| | | | - L Bruce Gladden
- School of Kinesiology, Auburn University, Auburn, AL, United States
| | - Robert D Arnold
- Harrison School of Pharmacy, Auburn University, Auburn, AL, United States
| | | | - Annie N Kirby
- Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine-Auburn Campus, Auburn, AL, United States
| | - Michael D Roberts
- School of Kinesiology, Auburn University, Auburn, AL, United States.,Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine-Auburn Campus, Auburn, AL, United States
| |
Collapse
|
39
|
Haun CT, Mobley CB, Vann CG, Romero MA, Roberson PA, Mumford PW, Kephart WC, Healy JC, Patel RK, Osburn SC, Beck DT, Arnold RD, Nie B, Lockwood CM, Roberts MD. Soy protein supplementation is not androgenic or estrogenic in college-aged men when combined with resistance exercise training. Sci Rep 2018; 8:11151. [PMID: 30042516 PMCID: PMC6057888 DOI: 10.1038/s41598-018-29591-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 07/02/2018] [Indexed: 12/14/2022] Open
Abstract
It is currently unclear as to whether sex hormones are significantly affected by soy or whey protein consumption. Additionally, estrogenic signaling may be potentiated via soy protein supplementation due to the presence of phytoestrogenic isoflavones. Limited also evidence suggests that whey protein supplementation may increase androgenic signaling. Therefore, the purpose of this study was to examine the effects of soy protein concentrate (SPC), whey protein concentrate (WPC), or placebo (PLA) supplementation on serum sex hormones, androgen signaling markers in muscle tissue, and estrogen signaling markers in subcutaneous (SQ) adipose tissue of previously untrained, college-aged men (n = 47, 20 ± 1 yrs) that resistance trained for 12 weeks. Fasting serum total testosterone increased pre- to post-training, but more so in subjects consuming WPC (p < 0.05), whereas serum 17β-estradiol remained unaltered. SQ estrogen receptor alpha (ERα) protein expression and hormone-sensitive lipase mRNA increased with training regardless of supplementation. Muscle androgen receptor (AR) mRNA increased while ornithine decarboxylase mRNA (a gene target indicative of androgen signaling) decreased with training regardless of supplementation (p < 0.05). No significant interactions of supplement and time were observed for adipose tissue ERα/β protein levels, muscle tissue AR protein levels, or mRNAs in either tissue indicative of altered estrogenic or androgenic activity. Interestingly, WPC had the largest effect on increasing type II muscle fiber cross sectional area values (Cohen's d = 1.30), whereas SPC had the largest effect on increasing this metric in type I fibers (Cohen's d = 0.84). These data suggest that, while isoflavones were detected in SPC, chronic WPC or SPC supplementation did not appreciably affect biomarkers related to muscle androgenic signaling or SQ estrogenic signaling. The noted fiber type-specific responses to WPC and SPC supplementation warrant future research.
Collapse
Affiliation(s)
- Cody T Haun
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - C Brooks Mobley
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Christopher G Vann
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Matthew A Romero
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Paul A Roberson
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Petey W Mumford
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Wesley C Kephart
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - James C Healy
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA.,Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine - Auburn Campus, Auburn, AL, USA
| | - Romil K Patel
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Shelby C Osburn
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA
| | - Darren T Beck
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA.,Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine - Auburn Campus, Auburn, AL, USA
| | - Robert D Arnold
- Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University Pharmaceutical Research Building, Auburn, AL, USA
| | - Ben Nie
- Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University Pharmaceutical Research Building, Auburn, AL, USA
| | | | - Michael D Roberts
- Molecular and Applied Sciences Laboratory, School of Kinesiology, Auburn University, Auburn, AL, USA. .,Department of Cell Biology and Physiology, Edward Via College of Osteopathic Medicine - Auburn Campus, Auburn, AL, USA.
| |
Collapse
|
40
|
Aldawsari MF, Lau VW, Babu RJ, Arnold RD, Platt SR. Pharmacokinetic evaluation of novel midazolam gel formulations following buccal administration to healthy dogs. Am J Vet Res 2018; 79:73-82. [PMID: 29287157 DOI: 10.2460/ajvr.79.1.73] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine the physiochemical properties and pharmacokinetics of 3 midazolam gel formulations following buccal administration to dogs. ANIMALS 5 healthy adult hounds. PROCEDURES In phase 1 of a 2-phase study, 2 gel formulations were developed that contained 1% midazolam in a poloxamer 407 (P1) or hydroxypropyl methylcellulose (H1) base and underwent rheological and in vitro release analyses. Each formulation was buccally administered to 5 dogs such that 0.3 mg of midazolam/kg was delivered. Each dog also received midazolam hydrochloride (0.3 mg/kg, IV). There was a 3-day interval between treatments. Blood samples were collected immediately before and at predetermined times for 8 hours after drug administration for determination of plasma midazolam concentration and pharmacokinetic analysis. During phase 2, a gel containing 2% midazolam in a hydroxypropyl methylcellulose base (H2) was developed on the basis of phase 1 results. That gel was buccally administered such that midazolam doses of 0.3 and 0.6 mg/kg were delivered. Each dog also received midazolam (0.3 mg/kg, IV). All posttreatment procedures were the same as those for phase 1. RESULTS The H1 and H2 formulations had lower viscosity, greater bioavailability, and peak plasma midazolam concentrations that were approximately 2-fold as high, compared with those for the P1 formulation. The mean peak plasma midazolam concentration for the H2 formulation was 187.0 and 106.3 ng/mL when the midazolam dose administered was 0.6 and 0.3 mg/kg, respectively. CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that buccal administration of gel formulations might be a viable alternative for midazolam administration to dogs.
Collapse
|
41
|
Pradhan S, Smith AM, Garson CJ, Hassani I, Seeto WJ, Pant K, Arnold RD, Prabhakarpandian B, Lipke EA. A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy. Sci Rep 2018; 8:3171. [PMID: 29453454 PMCID: PMC5816595 DOI: 10.1038/s41598-018-21075-9] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Accepted: 12/20/2017] [Indexed: 12/21/2022] Open
Abstract
Assessment of anti-cancer drug efficacy in in vitro three-dimensional (3D) bioengineered cancer models provides important contextual and relevant information towards pre-clinical translation of potential drug candidates. However, currently established models fail to sufficiently recapitulate complex tumor heterogeneity. Here we present a chip-based tumor-mimetic platform incorporating a 3D in vitro breast cancer model with a tumor-mimetic microvascular network, replicating the pathophysiological architecture of native vascularized breast tumors. The microfluidic platform facilitated formation of mature, lumenized and flow-aligned endothelium under physiological flow recapitulating both high and low perfused tumor regions. Metastatic and non-metastatic breast cancer cells were maintained in long-term 3D co-culture with stromal fibroblasts in a poly(ethylene glycol)-fibrinogen hydrogel matrix within adjoining tissue chambers. The interstitial space between the chambers and endothelium contained pores to mimic the “leaky” vasculature found in vivo and facilitate cancer cell-endothelial cell communication. Microvascular pattern-dependent flow variations induced concentration gradients within the 3D tumor mass, leading to morphological tumor heterogeneity. Anti-cancer drugs displayed cell type- and flow pattern-dependent effects on cancer cell viability, viable tumor area and associated endothelial cytotoxicity. Overall, the developed microfluidic tumor-mimetic platform facilitates investigation of cancer-stromal-endothelial interactions and highlights the role of a fluidic, tumor-mimetic vascular network on anti-cancer drug delivery and efficacy for improved translation towards pre-clinical studies.
Collapse
Affiliation(s)
- Shantanu Pradhan
- Department of Chemical Engineering, Auburn University, Auburn, AL, 36849, USA
| | - Ashley M Smith
- Biomedical Technology, CFD Research Corporation, Huntsville, AL, 35806, USA
| | - Charles J Garson
- Biomedical Technology, CFD Research Corporation, Huntsville, AL, 35806, USA
| | - Iman Hassani
- Department of Chemical Engineering, Auburn University, Auburn, AL, 36849, USA
| | - Wen J Seeto
- Department of Chemical Engineering, Auburn University, Auburn, AL, 36849, USA
| | - Kapil Pant
- Biomedical Technology, CFD Research Corporation, Huntsville, AL, 35806, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Auburn University, Auburn, AL, 36849, USA
| | | | - Elizabeth A Lipke
- Department of Chemical Engineering, Auburn University, Auburn, AL, 36849, USA.
| |
Collapse
|
42
|
Li Y, Rong Y, Bao L, Nie B, Ren G, Zheng C, Amin R, Arnold RD, Jeganathan RB, Huggins KW. Suppression of adipocyte differentiation and lipid accumulation by stearidonic acid (SDA) in 3T3-L1 cells. Lipids Health Dis 2017; 16:181. [PMID: 28946872 PMCID: PMC5613458 DOI: 10.1186/s12944-017-0574-7] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Accepted: 09/20/2017] [Indexed: 12/02/2022] Open
Abstract
Background Increased consumption of omega-3 (ω-3) fatty acids found in cold-water fish and fish oil has been reported to protect against obesity. A potential mechanism may be through reduction in adipocyte differentiation. Stearidonic acid (SDA), a plant-based ω-3 fatty acid, has been targeted as a potential surrogate for fish-based fatty acids; however, its role in adipocyte differentiation is unknown. This study was designed to evaluate the effects of SDA on adipocyte differentiation in 3T3-L1 cells. Methods 3T3-L1 preadipocytes were differentiated in the presence of SDA or vehicle-control. Cell viability assay was conducted to determine potential toxicity of SDA. Lipid accumulation was measured by Oil Red O staining and triglyceride (TG) quantification in differentiated 3T3-L1 adipocytes. Adipocyte differentiation was evaluated by adipogenic transcription factors and lipid accumulation gene expression by quantitative real-time polymerase chain reaction (qRT-PCR). Fatty acid analysis was conducted by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Results 3T3-L1 cells treated with SDA were viable at concentrations used for all studies. SDA treatment reduced lipid accumulation in 3T3-L1 adipocytes. This anti-adipogenic effect by SDA was a result of down-regulation of mRNA levels of the adipogenic transcription factors CCAAT/enhancer-binding proteins alpha and beta (C/EBPα, C/EBPβ), peroxisome proliferator-activated receptor gamma (PPARγ), and sterol-regulatory element binding protein-1c (SREBP-1c). SDA treatment resulted in decreased expression of the lipid accumulation genes adipocyte fatty-acid binding protein (AP2), fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD-1), lipoprotein lipase (LPL), glucose transporter 4 (GLUT4) and phosphoenolpyruvate carboxykinase (PEPCK). The transcriptional activity of PPARγ was found to be decreased with SDA treatment. SDA treatment led to significant EPA enrichment in 3T3-L1 adipocytes compared to vehicle-control. Conclusion These results demonstrated that SDA can suppress adipocyte differentiation and lipid accumulation in 3T3-L1 cells through down-regulation of adipogenic transcription factors and genes associated with lipid accumulation. This study suggests the use of SDA as a dietary treatment for obesity. Electronic supplementary material The online version of this article (10.1186/s12944-017-0574-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yueru Li
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA
| | - Yinghui Rong
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA
| | - Lisui Bao
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA
| | - Ben Nie
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA
| | - Guang Ren
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA
| | - Chen Zheng
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA
| | - Rajesh Amin
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.,Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL, USA
| | - Robert D Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.,Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL, USA
| | - Ramesh B Jeganathan
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA.,Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL, USA
| | - Kevin W Huggins
- Department of Nutrition, Dietetics and Hospitality Management, Auburn University, Auburn, AL, USA. .,Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL, USA.
| |
Collapse
|
43
|
Brown JC, Brainard BM, Fletcher DJ, Nie B, Arnold RD, Schmiedt CW. Effect of aminocaproic acid on clot strength and clot lysis of canine blood determined by use of an in vitro model of hyperfibrinolysis. Am J Vet Res 2016; 77:1258-1265. [DOI: 10.2460/ajvr.77.11.1258] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
44
|
Scholpa NE, Kolli RT, Moore M, Arnold RD, Glenn TC, Cummings BS. Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer. Chem Biol Interact 2016; 258:21-9. [PMID: 27543423 PMCID: PMC5045804 DOI: 10.1016/j.cbi.2016.08.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 07/21/2016] [Accepted: 08/15/2016] [Indexed: 12/25/2022]
Abstract
This study determined the anti-neoplastic activity and nephrotoxicity of epigenetic inhibitors in vitro. The therapeutic efficacy of epigenetic inhibitors was determined in human prostate cancer cells (PC-3 and LNCaP) using the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-Aza) and the histone deacetylase inhibitor trichostatin A (TSA). Cells were also treated with carbamazepine (CBZ), an anti-convulsant with histone deacetylase inhibitor-like properties. 5-Aza, TSA or CBZ alone did not decrease MTT staining in PC-3 or LNCaP cells after 48 h. In contrast, docetaxel, a frontline chemotherapeutic induced concentration-dependent decreases in MTT staining. Pretreatment with 5-Aza or TSA increased docetaxel-induced cytotoxicity in LNCaP cells, but not PC-3 cells. TSA pretreatment also increased cisplatin-induced toxicity in LNCaP cells. Carfilzomib (CFZ), a protease inhibitor approved for the treatment of multiple myeloma had minimal effect on LNCaP cell viability, but reduced MTT staining 50% in PC-3 cells compared to control, and pretreatment with 5-Aza further enhanced toxicity. Treatment of normal rat kidney (NRK) and human embryonic kidney 293 (HEK293) cells with the same concentrations of epigenetic inhibitors used in prostate cancer cells significantly decreased MTT staining in all cell lines after 48 h. Interestingly, we found that the toxicity of epigenetic inhibitors to kidney cells was dependent on both the compound and the stage of cell growth. The effect of 5-Aza and TSA on DNA methyltransferase and histone deacetylase activity, respectively, was confirmed by assessing the methylation and acetylation of the CDK inhibitor p21. Collectively, these data show that combinatorial treatment with epigenetic inhibitors alters the efficacy of chemotherapeutics in cancer cells in a compound- and cell-specific manner; however, this treatment also has the potential to induce nephrotoxic cell injury.
Collapse
Affiliation(s)
- N E Scholpa
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA
| | - R T Kolli
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA
| | - M Moore
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA
| | - R D Arnold
- Department of Drug Discovery and Development, Auburn University, Auburn, AL 36849, USA
| | - T C Glenn
- Department of Environmental Health Science, University of Georgia, Athens, GA 30602, USA
| | - B S Cummings
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA.
| |
Collapse
|
45
|
Dixon-Jimenez AC, Brainard BM, Brooks MB, Nie B, Arnold RD, Loper D, Abrams JC, Rapoport GS. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats. J Vet Emerg Crit Care (San Antonio) 2016; 26:619-29. [DOI: 10.1111/vec.12524] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 03/30/2015] [Accepted: 05/18/2015] [Indexed: 02/01/2023]
Affiliation(s)
- Amy C. Dixon-Jimenez
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine; University of Georgia; Athens GA 30602
| | - Benjamin M. Brainard
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine; University of Georgia; Athens GA 30602
| | - Marjory B. Brooks
- the Department of Population Medicine and Diagnostic Sciences; College of Veterinary Medicine, Cornell University; Ithaca NY 14850
| | - Ben Nie
- Department of Drug Discovery and Development, Harrison School of Pharmacy; Auburn University; Auburn AL 36849
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy; Auburn University; Auburn AL 36849
| | - Daniel Loper
- Pharmaceutical Specialties, Inc; Bogart GA 30622
| | - Jessica C. Abrams
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine; University of Georgia; Athens GA 30602
| | - Gregg S. Rapoport
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine; University of Georgia; Athens GA 30602
| |
Collapse
|
46
|
Pradhan S, Smith AM, Garson CJ, Hassani I, Pant K, Arnold RD, Prabhakarpandian B, Lipke EA. Abstract 620: Microfluidic cancer-on-a-chip platform for assessing anti-cancer drug efficacies. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-620] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The tumor microenvironment is known to play an influential role in the angiogenic and metastatic progression of cancer and is regulated by different factors (stromal fibroblasts, extracellular matrix (ECM) proteins and endothelial cells) present in the complex milieu. Recapitulation of this complexity in three-dimensional (3D) tumor models is critical in understanding the processes involved in cancer progression and to provide clinically relevant efficacy data for cancer drugs. To address this challenge, we developed a microfluidic oncomimetic platform where breast cancer cells are co-cultured with fibroblasts along with a complex, intricate vascular network. We further investigated the effect of mechanical stiffness of the tumor stroma on the growth and morphology of cancer cells, migration of cancer cells into surrounding vasculature and the ability of standard cancer drugs to perfuse through the vasculature and target cancer cells.
Materials and Methods: Poly(dimethyl siloxane) (PDMS)-based microfluidic devices, containing vascular networks in communication with tumor chamber, were fabricated using photolithography as described earlier1. Poly(ethylene glycol)-fibrinogen (PEG-Fb), used for 3D co-culture of cancer cells and fibroblasts, was prepared using established protocols2. Human breast tumor associated endothelial cells (hBTECs) were seeded within fibronectin-coated vascular channels and maintained under flow to develop endothelial networks. To obtain 3D cancer-fibroblast co-culture system, MCF7 or MDA-MB-231 breast cancer cells were co-encapsulated with BJ-5ta human fibroblasts in PEG-Fb hydrogel in the tumor chamber. Immunostaining with standard endothelial and cancer markers was conducted to confirm maturity and functionality of seeded cells. GFP-labelled cancer cells were co-cultured with hBTECs to visualize tumor cell migration. Cancer cells were also maintained in culture over several weeks within the devices to demonstrate applicability of this system to perform long-term drug dosing experiments. Finally, the cytotoxic effects of doxorubicin and paclitaxel at two different concentrations on cancer cells were evaluated by perfusing the drugs through the endothelial channels and cell viability quantified via Live/Dead staining.
Conclusions: We have developed a novel 3D microfluidic, vascularized cancer-fibroblast co-culture platform, with the ability to predict drug efficacy for breast cancer. This platform can also be extended in future for cancer-immunotherapy based investigations and screening of novel nano-carrier based anti-cancer drugs.
Acknowledgements: We gratefully acknowledge financial support from NIH (#HHSN261201400037C) and AURIC.
References: 1. B. Prabhakarpandian et al., J Control Release 2015; 201:49-55
2. L. Almany et al., Biomaterials 2005; 26(15):2467-77
Citation Format: Shantanu Pradhan, Ashley M. Smith, Charles J. Garson, Iman Hassani, Kapil Pant, Robert D. Arnold, Balabhaskar Prabhakarpandian, Elizabeth A. Lipke. Microfluidic cancer-on-a-chip platform for assessing anti-cancer drug efficacies. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 620.
Collapse
Affiliation(s)
| | | | | | | | - Kapil Pant
- 2CFD Research Corporation, Huntsville, AL
| | | | | | | |
Collapse
|
47
|
Chaudhari AA, Ashmore D, Nath SD, Kate K, Dennis V, Singh SR, Owen DR, Palazzo C, Arnold RD, Miller ME, Pillai SR. A novel covalent approach to bio-conjugate silver coated single walled carbon nanotubes with antimicrobial peptide. J Nanobiotechnology 2016; 14:58. [PMID: 27412259 PMCID: PMC4944237 DOI: 10.1186/s12951-016-0211-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 06/30/2016] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Due to increasing antibiotic resistance, the use of silver coated single walled carbon nanotubes (SWCNTs-Ag) and antimicrobial peptides (APs) is becoming popular due to their antimicrobial properties against a wide range of pathogens. However, stability against various conditions and toxicity in human cells are some of the major drawbacks of APs and SWCNTs-Ag, respectively. Therefore, we hypothesized that APs-functionalized SWCNTs-Ag could act synergistically. Various covalent functionalization protocols described previously involve harsh treatment of carbon nanotubes for carboxylation (first step in covalent functionalization) and the non-covalently functionalized SWCNTs are not satisfactory. METHODS The present study is the first report wherein SWCNTs-Ag were first carboxylated using Tri sodium citrate (TSC) at 37 °C and then subsequently functionalized covalently with an effective antimicrobial peptide from Therapeutic Inc., TP359 (FSWCNTs-Ag). SWCNTs-Ag were also non covalently functionalized with TP359 by simple mixing (SWCNTs-Ag-M) and both, the FSWCNTs-Ag (covalent) and SWCNTs-Ag-M (non-covalent), were characterized by Fourier transform infrared spectroscopy (FT-IR), Ultraviolet visualization (UV-VIS) and transmission electron microscopy (TEM). Further the antibacterial activity of both and TP359 were investigated against two gram positive (Staphylococcus aureus and Streptococcus pyogenes) and two gram negative (Salmonella enterica serovar Typhimurium and Escherichia coli) pathogens and the cellular toxicity of TP359 and FSWCNTs-Ag was compared with plain SWCNTs-Ag using murine macrophages and lung carcinoma cells. RESULTS FT-IR analysis revealed that treatment with TSC successfully resulted in carboxylation of SWCNTs-Ag and the peptide was indeed attached to the SWCNTs-Ag evidenced by TEM images. More importantly, the present study results further showed that the minimum inhibitory concentration (MIC) of FSWCNTs-Ag were much lower (~7.8-3.9 µg/ml with IC50: ~4-5 µg/ml) compared to SWCNTs-Ag-M and plain SWCNTs-Ag (both 62.6 µg/ml, IC50: ~31-35 µg/ml), suggesting that the covalent conjugation of TP359 with SWCNTs-Ag was very effective on their counterparts. Additionally, FSWCNTs-Ag are non-toxic to the eukaryotic cells at their MIC concentrations (5-2.5 µg/ml) compared to SWCNTs-Ag (62.5 µg/ml). CONCLUSION In conclusion, we demonstrated that covalent functionalization of SWCNTs-Ag and TP359 exhibited an additive antibacterial activity. This study described a novel approach to prepare SWCNT-Ag bio-conjugates without loss of antimicrobial activity and reduced toxicity, and this strategy will aid in the development of novel and biologically important nanomaterials.
Collapse
Affiliation(s)
- Atul A. Chaudhari
- />Center for Nanobiotechnology Research, Alabama State University, Montgomery, AL USA
| | - D’andrea Ashmore
- />Center for Nanobiotechnology Research, Alabama State University, Montgomery, AL USA
| | - Subrata deb Nath
- />Department of Mechanical Engineering, University of Louisville, Louisville, KY USA
| | - Kunal Kate
- />Department of Mechanical Engineering, University of Louisville, Louisville, KY USA
| | - Vida Dennis
- />Center for Nanobiotechnology Research, Alabama State University, Montgomery, AL USA
| | - Shree R. Singh
- />Center for Nanobiotechnology Research, Alabama State University, Montgomery, AL USA
| | - Don R. Owen
- />Therapeutic Peptides Inc., 7053 Revenue Drive, Baton Rouge, LA 70809 USA
| | - Chris Palazzo
- />Therapeutic Peptides Inc., 7053 Revenue Drive, Baton Rouge, LA 70809 USA
| | - Robert D. Arnold
- />Department of Drug Discovery and Development, Auburn University, Auburn, AL USA
| | - Michael E. Miller
- />Research Instrumentation Facility, Auburn University, Auburn, AL USA
| | - Shreekumar R. Pillai
- />Center for Nanobiotechnology Research, Alabama State University, Montgomery, AL USA
| |
Collapse
|
48
|
Pati S, Nie B, Arnold RD, Cummings BS. Extraction, chromatographic and mass spectrometric methods for lipid analysis. Biomed Chromatogr 2016; 30:695-709. [PMID: 26762903 PMCID: PMC8425715 DOI: 10.1002/bmc.3683] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 01/07/2016] [Accepted: 01/07/2016] [Indexed: 01/21/2023]
Abstract
Lipids make up a diverse subset of biomolecules that are responsible for mediating a variety of structural and functional properties as well as modulating cellular functions such as trafficking, regulation of membrane proteins and subcellular compartmentalization. In particular, phospholipids are the main constituents of biological membranes and play major roles in cellular processes like transmembrane signaling and structural dynamics. The chemical and structural variety of lipids makes analysis using a single experimental approach quite challenging. Research in the field relies on the use of multiple techniques to detect and quantify components of cellular lipidomes as well as determine structural features and cellular organization. Understanding these features can allow researchers to elucidate the biochemical mechanisms by which lipid-lipid and/or lipid-protein interactions take place within the conditions of study. Herein, we provide an overview of essential methods for the examination of lipids, including extraction methods, chromatographic techniques and approaches for mass spectrometric analysis.
Collapse
Affiliation(s)
- Sumitra Pati
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA
| | - Ben Nie
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Robert D. Arnold
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Brian S. Cummings
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
49
|
Huang J, Milton A, Arnold RD, Huang H, Smith F, Panizzi JR, Panizzi P. Methods for measuring myeloperoxidase activity toward assessing inhibitor efficacy in living systems. J Leukoc Biol 2016; 99:541-8. [PMID: 26884610 DOI: 10.1189/jlb.3ru0615-256r] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 01/11/2016] [Indexed: 12/23/2022] Open
Abstract
Myeloperoxidase aids in clearance of microbes by generation of peroxidase-mediated oxidants that kill leukocyte-engulfed pathogens. In this review, we will examine 1) strategies for in vitro evaluation of myeloperoxidase function and its inhibition, 2) ways to monitor generation of certain oxidant species during inflammation, and 3) how these methods can be used to approximate the total polymorphonuclear neutrophil chemotaxis following insult. Several optical imaging probes are designed to target reactive oxygen and nitrogen species during polymorphonuclear neutrophil inflammatory burst following injury. Here, we review the following 1) the broad effect of myeloperoxidase on normal physiology, 2) the difference between myeloperoxidase and other peroxidases, 3) the current optical probes available for use as surrogates for direct measures of myeloperoxidase-derived oxidants, and 4) the range of preclinical options for imaging myeloperoxidase accumulation at sites of inflammation in mice. We also stress the advantages and drawbacks of each of these methods, the pharmacokinetic considerations that may limit probe use to strictly cell cultures for some reactive oxygen and nitrogen species, rather than in vivo utility as indicators of myeloperoxidase function. Taken together, our review should shed light on the fundamental rational behind these techniques for measuring myeloperoxidase activity and polymorphonuclear neutrophil response after injury toward developing safe myeloperoxidase inhibitors as potential therapy for chronic obstructive pulmonary disease and rheumatoid arthritis.
Collapse
Affiliation(s)
- Jiansheng Huang
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| | - Amber Milton
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| | - Robert D Arnold
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| | - Hui Huang
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| | - Forrest Smith
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| | - Jennifer R Panizzi
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| | - Peter Panizzi
- *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA
| |
Collapse
|
50
|
Kephart WC, Wachs TD, Thompson RM, Mobley CB, Fox CD, McDonald JR, Ferguson BS, Young KC, Nie B, Martin JS, Company JM, Pascoe DD, Arnold RD, Moon JR, Roberts MD. Ten weeks of branched chain amino acid supplementation improves select performance and immunological variables in trained cyclists. J Int Soc Sports Nutr 2015. [PMCID: PMC4595557 DOI: 10.1186/1550-2783-12-s1-p20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|